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The discovery of cisplatin (cis-Pt(NH3)2Cl2) as an antineoplastic agent has focused attention on the 
rational design of metal complexes that can be potentially used in cancer chemotherapy. Today, the 
pharmaceutical industry invests more than $1 billion each year in the development of new metal-
based drugs to improve biological activities, in terms of cellular selectivity, therapeutic efficiency 
and minimization of side effects. Chemotherapies based on transition metals play a key role in 
cancer treatment, and among them platinum and palladium are the most fruitful. This article reviews 
the main recent advances in the design and synthesis of platinum- and palladium-based drugs, their 
structural features and biological studies of them. The rationale for the choice of the ligand, related 
to leaving groups, the geometry of the complex and the oxidation state of the metal ion, is 
discussed. An overview of the main biological techniques and approaches for testing the interaction 
of these molecules with the biological environment, mainly DNA, to validate the effect is also 
provided.  
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1. Introduction 
Cancer is one of the main causes of morbidity and death worldwide, with approximately 14 million 
new cases and 8.2 million cancer-related deaths reported in 2012, thus affecting life expectancy and 
producing a negative impact on society [1]. 
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The discovery of cisplatin (cis-Pt(NH3)2Cl2) as an antineoplastic agent has focused attention on the 
rational design of metal complexes that can be potentially used in cancer chemotherapy [2-6]. 
Today, the pharmaceutical industry invests more than $1 billion each year in the development of 
new metal-based drugs with improved biological activities, in terms of cellular selectivity and 
therapeutic efficiency, but also to minimize side effects [7-9]. Serious side effects such as emesis, 
renal toxicity, bone marrow suppression, neurotoxicity, hearing loss and drug resistance are 
connected with the use of cisplatin in clinical application [10].  
The economic interest in metal-based compounds for pharmaceutical uses is also attested by the 
appearance of more than 60 patents in the period from 2013 to 2015 concerning only platinum 
complexes for tumour treatments. 
Despite the interest in new metal ions, platinum complexes are, at present, the only metal-based 
drugs currently used in clinical settings (Figure 1), and about 10 other platinum complexes are 
currently in clinical trials [11].  
However, research on other metal complexes is constantly increasing, and many metal ions, mainly 
belonging to the class of noble metals, have been studied [12]. Among them, interest in palladium is 
increasing because it forms complexes similar to platinum but with different kinetics and stability of 
both the main ligand and the leaving groups and, in addition, at a lower cost.  
Cisplatin is still considered the main architecture for the main development of platinum-based and 
other metal-based systems. This is because the platinum drugs used in the clinic up to now are 
similar to cisplatin, exerting the same mechanism of action in which the cross-linking of DNA by 
covalent bonds is predominant. At the same time, because these complexes are structurally derived 
from cisplatin, the drawbacks of cisplatin are inherited. This has resulted in many scientists being 
engaged in the design of novel metal complexes deriving not only from the cisplatin architecture 
but also from different architectures, such as monofunctional complexes [13,14] and positively 
charged multinuclear complexes [15]. Therefore, further molecular architectures and oxidation 
states are continuously being prepared with the aim to improve the efficacy and specificity in 
tumour treatments. 
In Figure 2 the main approaches in the design of novel platinum-based drugs are reported, together 
with some examples of complexes that have been studied or are being studied.  
In this review, we consider platinum and palladium complexes developed for antineoplastic aims in 
the period from 2013 to 2015. The complexes are grouped and discussed essentially following the 
guidelines in Figure 2. The approaches and results are discussed, focusing on the type of complexes 
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developed, their topology and the corresponding structural aspects. We also discuss the main 
biological approaches used to validate the efficacy of the complexes.  
 
2. Cisplatin-like complexes 
2.1. Platinum(II) complexes 
Since the quite serendipitous discovery of cisplatin antitumour activity [16] (Figure 1), a plethora of 
strictly related platinum complexes have been invented, synthesized and tested. Carboplatin, 
oxaliplatin (both marketed worldwide), nedaplatin (approved in Japan), lobaplatin (approved in 
China), heptaplatin (approved in Korea) [3c,17] (Figure 1), and picoplatin are the result of the 
search for new and better performing (less toxic, broader activity spectrum, overcome drug 
resistance, etc.) anticancer platinum drugs originating from cisplatin by replacement of chloride 
and/or amine ligands. The rationale behind the design of cisplatin analogues rests both on the results 
of mechanistic investigations and on simple coordination chemistry considerations. These neutral 
complexes (which must be sufficiently water soluble), with general formula [PtX2(A)n], feature two 
leaving groups (X) in the cis position, with the other two positions of the square planar structure 
being typically occupied by the amine nitrogen atom provided by two monodentate ligands (A, n=2) 
or one bidentate chelating diamine (A, n=1). Once within the cell (chemical neutrality and high 
lipophilicity allow easy penetration of the complex into the cell), one or both X ligands are lost and 
replaced by water molecules. As a consequence, the donor atoms of the X anion, typically chloride, 
iodide and oxygen atoms, should bind the metal ion neither too weakly (to avoid toxic effects due to 
the high reactivity) nor too strongly (leading to inactive drugs). In this respect, the soft nature of the 
Pt(II) ion could help in the choice of suitable donor atoms. This is because the ligand A usually 
contains nitrogen as the donor atom, which guarantees thermodynamically stable bonds with 
platinum that are preserved even in the adduct formed with DNA. The latter is formed when the 
platinum ion of the aquated species covalently binds to the nitrogen atom at the 7-position of 
purines, losing the water molecules. The resulting adduct is quite stable kinetically, given that 
amines and heterocyclic nitrogen ligands have a low trans effect (another parameter that must be 
taken into account in the design of new cisplatin analogues [18]). Owing to the cis geometry of the 
metal complex, 1,2-intrastrand cross-links are formed between adjacent guanines as are 1,3-
intrastrand cross-links (for geometric reasons, the trans isomer cannot form cross-links of this 
kind). The resulting intrastrand adduct, which distorts and bends DNA, causes different cellular 




In addition, the solid-state structures of cisplatin [19,20] and most of the marketed [21-27], 
promising [28-31] and even not promising congeners have been determined by single-crystal X-ray 
diffraction, thus adding further details to the “classical” structure-activity relationships first 
recognized by Cleare and Hoeschele [32-35]. Knowledge of the molecular structure, other than 
providing obvious information (e.g. usual/unusual bond distances and angles about the Pt(II) ion, its 
square planar coordination geometry and the cis arrangement of the leaving groups), can suggest 
useful correlations with efficacy and with the observed physicochemical properties, as briefly 
outlined in the following. For example, single-crystal X-ray diffraction can reveal the enantiomer 
composition of a crystalline sample, and we know that chirality [36,37] can play an important role 
in determining the performance of a platinum-based anticancer drug, as evidenced by oxaliplatin 
[38]. On the other hand, it might be difficult for bulky N-donor ligands to penetrate the cell but, at 
the same time, once inside the tumour cell, they may play a positive role; in fact, they, due to their 
dimension, can hinder the recognition of DNA damage and its subsequent repair. In this respect, 
single-crystal X-ray diffraction can provide hints about the steric hindrance of the coordinated 
ligands and/or their relative repulsion by revealing, for example the relative orientation, 
intramolecular contacts, and deviations from the ideal geometry [39-42]. On the other hand, 
determination of the crystal structure and the subsequent study of the crystal packing can help to 
rationalize the tendency of the platinum drug to be involved in intermolecular interactions of the 
NH∙∙∙O type, which are considered the first step in approaching DNA; hence, the presence in the 
platinum drugs of NH3/NH2R/NHR2, which are able to form hydrogen bonds with DNA peripheral 
phosphates, as non-leaving groups. In addition, the latter could contribute to stabilization of the 
drug-DNA adduct formed once the coordinating water molecules have been lost [43,44]. 
For all these reasons, it is interesting to analyse in depth the crystal packing of hydrated/solvated 
(solvent molecules should behave as hydrogen-bond acceptors) platinum drugs to form a picture of 
the hydrogen-bond donor ability of the platinum complexes [45,46]. Conversely, the lack of co-
crystallized solvent molecules and/or complex self-association can be related to poor or even absent 
solubility [45,47]. This kind of analysis can provide indirect information on the hydrophilicity-
lipophilicity balance, which is an essential requisite for a platinum-drug complex [47]. As a final 
remark, the occurrence in the crystal of stacking interactions between ad hoc functional groups 
bound to the metal ion suggests the likelihood of further stabilizing interactions in the drug-DNA 
adduct (see later). 
In this context, modelling (ab initio, density functional theory, molecular mechanics/quantum 
mechanics and docking are the most popular techniques) is a helpful complementary approach 
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which can provide hints for the rational design of novel species [48,49] or can be used to obtain 
structural/energetic/electronic information about the metal complexes [50,51] and/or the postulated 
corresponding adducts [52,53]. In this section, the most recent and fruitful advances in the 
optimization of the structure of cisplatin-like compounds are described. 
 
2.1.1. Leaving group 
It is well known that the nature of the leaving ligand plays a significant role in determining the 
toxicity and side effects of a platinum drug, because the capability of different ligands to leave the 
binding platinum atom can result in a remarkably altered biodistribution in vivo. In general, 
complexes with labile anionic leaving groups, such as the chloride anion in cisplatin, which 
hydrolyse relatively fast, are much more toxic. The resulting reactive platinum intermediates can 
efficiently bind biomolecules such as sulfur-containing amino acids and peptides or proteins in the 
blood, and their interactions with proteins in organs such as the kidney can cause severe adverse 
effects. In contrast, less labile leaving groups, such as iodide, give rise to inactive molecules. 
Complexes with weakly labile anionic leaving groups, such as the dicarboxylate moiety in 
carboplatin, which hydrolyse slowly, are divided into two types: (1) water-soluble platinum 
complexes, which are stable and have a longer half-time in the blood, are less toxic because they 
can be excreted efficiently via the kidneys but their antitumour abilities are clearly reduced; (2) 
water-insoluble (lipophilic) platinum complexes, which hydrolyse slowly, are cleared much more 
easily from the blood through tissue penetration; in this way, some typical toxic side effects derived 
from cisplatin-based therapy are absent because of the reduced requirement for renal excretion. 
Thousands of platinum complexes have been designed, synthesized and biologically evaluated, but 
none have entered worldwide clinical use except oxaliplatin (which exhibits potent anticancer 
activity as a result of the presence of the [(R,R)-1,2-diaminocyclohexane]platinum(II) fragment as 
well as because of its good aqueous solubility and stability derived from the dicarboxylate leaving 
ligand. Thus, it seems impossible or extremely difficult to obtain a platinum anticancer agent with 
the characteristics of both potent anticancer activity, such as cisplatin, and low toxicity together 
with good water solubility and stability, such as carboplatin [47]. 
 
Dicarboxylates 
Bidentate dicarboxylates (e.g. 1,1-cyclobutanedicarboxylate and oxalate) are a type of common and 
effective alternative ligand to chloride anions. They can effectively improve the water solubility 
and/or lipophilicity of the resulting platinum complexes as compared with cisplatin. Moreover, the 
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chelating ring formed by the O,O-donors of the dicarboxylate and the platinum atom can increase 
the stability of the complexes and reduce the side effects of the corresponding platinum complexes. 
Furthermore, the nature of the leaving group determines different activities towards different cell 
lines. For example Xu et al. [54] demonstrated that by the introduction of an OH group at the 3-
position of the 1,1-cyclobutane dicarboxylate in C1a to obtain C1b (Figure 4), the activity against 
the A549 and HCT cell lines increases but against the MCF-7 tumour cell line it decreases. 
The same group [47] synthesized the ligands C2 and C3 (Figure 4), in which the 3-oxocyclobutane-
1,1-dicarboxylate leaving group showed potent in vitro anticancer activity, comparable with that of 
cisplatin and oxaliplatin, and low short-term toxicity, similar to that of carboplatin; moreover, the 
complexes had acceptable solubility and stability in water. Chemical and biological results 
indicated that both the potent anticancer activity and the low apparent toxicity of the platinum 
complexes derived from the kinetic properties of the compounds; in fact, the introduction of a 
carbonyl group enhances both the water solubility and the lability of the leaving group. 
Liu et al. [55] synthesized a series of oxaliplatin-like compounds in which the oxalate anion was 
replaced by 1,1-cyclobutane dicarboxylate derivatives in order to obtain complexes with the activity 
of oxaliplatin and to overcome the neurotoxicity of the oxalate anion. In particular, the derivative 
C4 (Figure 4), bearing the acetyl group at the 3-position of the dicarboxylcyclobutane moiety, 
exhibited high antitumour activity and less toxicity than oxaliplatin, which was ascribed to its 
optimal water solubility. 
Following the aim to increase both water solubility and cell membrane penetration, Sun et al. [56] 
synthesized a series of oxaliplatin derivatives with (R,R)-N-alkylcyclohexane-1,2-diamine as carrier 
ligands and 1-(methoxy- or methyl-substituted benzyl)azetidine-3,3-dicarboxylate anions as leaving 
groups. Generally, C5a-C5f (Figure 4), with an isopropyl substituent on the amine carrier ligand, 
exhibited higher activities in vitro than carboplatin against the MCF-7 human breast carcinoma and 
A549 human non-small-cell lung cell lines, although they were less potent than oxaliplatin. C5e 
exhibited cytotoxicity superior to that of carboplatin and comparable to that of oxaliplatin towards 
the two above tumour cell lines. The presence of the tertiary amine on the leaving group makes this 
complex particularly active in acidic media, such as the cytoplasm of cancer cells. 
With regard to water solubility and the capability to cross the cell membrane, Liu et al. [57] 
designed three glucose-conjugated malonate-Pt(II) complexes (Figure 4, C6) to target tumour-
specific active glucose transporters. The complexes exhibited 150 times higher aqueous solubility, 




As the leaving group was hydrolytically lost in the cytoplasm, this clearly represents an important 
issue in drug management. For this reason, as a valid alternative, the leaving group could be 
functionalized with bioactive moieties and thus the platinum complex could act as both a DNA 
cross-link inducer and an inducer of a different apoptosis mechanism. 
For example Liu et al. [58,59] synthesized a series of new diamine platinum complexes containing a 
dichloroacetate moiety as a small-molecule cell apoptosis inducer; they did this by introducing 3-
dichoroacetoxylcyclobutane-1,1-dicarboxylate as the leaving group in platinum complexes C7a-
C7f (Figure 5). Dichloroacetate can be efficiently released under physiological conditions via the 
hydrolysis of the ester bond, thus supporting the evaluation of these complexes as drug candidates. 
Zhao et al. [60] synthesized a series of Pt(II) complexes of N-monoalkyl-(R,R)-1,2-
diaminocylclohexanes with 3-(nitrooxy)cyclobutane-1,1-dicarboxylate as the leaving group (Figure 
5, C8). These compounds showed high cytotoxicity towards human cancer cell lines, and their 
activity is enhanced by the release of NO in the presence of L-cysteine, based on the fact that thiols 
can induce the release of NO from organic nitrates in vitro. NO is well known for its biological 
functions in vasodilation, neurotransmission and the immune system and as a cell apoptosis inducer. 
Moreover, NO prodrugs may act synergistically with the platinum-based moieties on the tumour 
cells; such NO-donor compounds can improve the anticancer efficacy and can reduce the resistance 
of human cancer cells to platinum drugs. 
Parker et al. [49] reported the design and synthesis of a novel Pt(II) complex of the histone 
deacetylase inhibitor belinostat conjugated to the malonate leaving group (C9, Figure 5). This 
complex is considerably cytotoxic to ovarian cancer cell lines, and favourable cytoselective 
properties as compared with cisplatin alone and belinostat alone. 
 
Other leaving groups 
To investigate the difference between the reactivity of halogens and carboxylate, Zhao et al. [61] 
synthesized three platinum complexes with both a chloride anion and a chelated carboxylate as 
leaving groups (C10a-C10c, Figure 6). All the compounds exhibited effective cytotoxicity towards 
tumour cell lines, nearly comparable to the cytotoxicity of cisplatin and oxaliplatin. Notably, the 
activity of C10b was about twofold better than that of oxaliplatin against the HCT 116 cell line. 
Chloride anion departs from the Pt(II) quickly, whereas the five- or six-membered ring formed by 
coordinated N,O-donors opened more slowly by the breaking of a Pt−O bond. This helped to further 
understand the mechanism of action of these complexes with biomolecules. The same research 
group [62] developed the dinuclear complexes C11 (Figure 6), in which a dicarboxylate or a sulfate 
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ligand, in place of a chlorine, bridged two C10c units. The in vitro cytotoxicity of these compounds 
towards several cell lines was evaluated. All the compounds are cytotoxic towards the HepG2 cell 
line. Particularly, C11d, with the SO4
2- bridge, exhibited better cytotoxicity than carboplatin or 
oxaliplatin towards all cell lines tested. 
Valiahdi [63] described a series of bis(2-aminoalcoholato-N,O)platinum(II) complexes (Figure 6, 
C12) with low systemic toxicity; they achieved their full antitumour potency only in acidic 
conditions. These complexes are activated by protonation of the alcoholate oxygen, resulting in the 
cleavage of Pt–O bonds. The paradigm is that extracellular acidity is a frequent pathophysiological 
condition of solid tumours, and these compounds offer possibilities for improving the tumour 
selectivity for molecular therapy. 
Cisplatin-like drugs with iodide as the leaving group are quite rare owing to their slow reaction rate. 
An example of a moderately active molecule has been reported by Savić et al. [50]; they 
synthesized a class of ligand in which the cis-PtI2 moiety was coordinated by isobutyl, n-pentyl and 
isopentyl esters of (S,S)-1,3-propanediamine-N,N'-bis[2-(3-cyclohexyl)propanoic acid] (Figure 6, 
C13). The comparison of the structure-activity relationship indicated variations of cytotoxicity 
related to the drug/ligand lipophilicity, whereas the intracellular platinum content and DNA 
platination increased with increasing length and branching of the ester chain. The half maximal 
inhibitory concentrations (IC50 values) ranged between 5 and 30 μM and are of the same order as 
for cisplatin for all cell lines tested. 
 
2.1.2. Amine carrier ligands 
The structural characteristics of oxaliplatin, which has (R,R)-1,2-diaminocyclohexane as the carrier 
ligand instead of the two ammonia groups of cisplatin, suggested that 1,2-diaminocyclohexane may 
be a useful pharmacophore for the design of novel platinum-based complexes. Many platinum-
based complexes containing 1,2-diaminocyclohexane have been previously, and some of them 
showed good results. However, to further explore such pharmacophores, many 1,2-
diaminocyclohexane derivatives and other amine ligands have been prepared and used as platinum-
based drugs. Some research groups reported a class of N-alkyl derivatives of (R,R)-1,2-
diaminocyclohexane that can be used as carrier ligands for novel Pt(II)-based antitumour 
complexes. The introduction of the alkyl groups to 1,2-diaminocyclohexane may improve the 
properties of the resulting Pt(II) complexes as follows: (1) changing the substituted group may 
adjust the balance between the lipophilicity and hydrophilicity of the complex so that an optimal 
log P (P is the partition coefficient between an organic solvent and water) value of the complexes 
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can be expected; (2) the steric hindrance of the substituted group may change the mode of the 
interaction between the complex and DNA, which is the main target of the platinum-based drugs; 
this may subsequently affect antitumour properties. 
Fang et al. [64] produced a series of novel Pt(II) complexes with N-monoalkyl (R,R)-1,2-
diaminocyclohexane derivatives as amine ligands and 3-hydroxycyclobutane-1,1-dicarboxylate as 
the leaving group (Figure 7, C14a-C14g). In particular, C14d, with the sec-butyl group, showed 
much higher cytotoxic activity than carboplatin and oxaliplatin against the MCF-7 and A549 cell 
lines. Because of the use of N-monoalkyl (R,R)-1,2-diaminocyclohexane derivatives and 3-
hydroxycyclobutane-1,1-dicarboxylate as ligands, the calculated log P values of the complexes are 
around 1; this suggests a good balance between lipophilicity and hydrophilicity. The same group 
[65] studied four Pt(II) complexes of (R,R)-N1,N2-dibutyl-1,2-diaminocyclohexane with two alkyl 
branches as steric hindrance (Figure 7, C15a-C15d). The in vitro cytotoxicity of these compounds 
indicated C15d is the most cytotoxic agent; it was more active than its parent molecule oxaliplatin 
against almost all the cell lines tested. In agarose gel electrophoresis studies, the kinetic reactivity of 
C15d with DNA is slow because of the steric hindrance effect, demonstrating that it may possess a 
molecular mechanism of action different from that of cisplatin. Nevertheless, the global effect is an 
apoptotic mechanism similar to that of cisplatin, which could induce apoptosis via a mitochondrial-
dependent pathway. 
Gay et al. [37] investigated the structure-activity relationships of several organic functionalities 
(C=C double bond, free OH group, MeO group, etc.) and the effect of the stereochemistry on the 
cytotoxic activity of selected Pt(II) complexes having differently functionalized 1,2-
bis(aminomethyl)cyclohexane carrier ligands with a 1,4-diamino framework and iodide as labile 
ligands (C16, Figure 7). In comparison with cisplatin, these platinum complexes exhibited up to 16 
times lower resistance factors in A2780cisR ovarian cancer cells. This cell line becomes drug 
resistant because of a combination of effects, among them reduced drug transport, enhanced DNA 
repair/tolerance and an elevated glutathione level with respect to the parental A2780 cells.  
Another approach to improve the cellular accumulation of cisplatin-like compounds is to replace the 
aliphatic amine ligand with azaheterocycles or aromatic amines. Good results were obtained by the 
introduction of 7-azaindole halogen derivatives. Muchova et al. [66] synthesized ligands C17 
(Figure 7); they were toxic to ovarian tumour cells, with moderately better IC50 values than cisplatin 
in the cisplatin-sensitive cell line A2780. The potential factors which might be involved in the 
mechanism underlying the cytotoxic effects of these compounds originate mainly from their 
efficient cellular accumulation. Other examples of N-heterocycle cisplatin-like complexes have 
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been reported by Štarha et al. [67] and Łakomska et al. [42] with use of 1,2,4-triazol-[1,5a]-
pyrimidine and 7-azaindole, C18 and C17 (Figure 7), respectively. The applicability of these 
complexes and their fate in biological systems are characterized by their hydrolytic stability and by 
the thermodynamic aspects of their interactions with cysteine, reduced glutathione, and human 
serum albumin. Serebryanskaya et al. [68] studied a series of cis-tetraazole- and trans-tetraazole-
containing Pt(II) and Pd(II) chloride complexes, discovering compound C19 (Figure 8), with 
noticeable efficacy in vivo. Ferri et al. [69] synthesized a series of imidazole-based Pt(II) complexes 
(C20, Figure 8); they evaluated their cytotoxicity towards a cancer cell line partially resistant to 
cisplatin but sensitive to oxaliplatin. The design of these compounds, having a heterocycle and an 
amine N-donor, preserved the aliphatic amino function in order to display the optimum trans effect 
and introduced a chain of appropriate length at the imidazole moiety to improve the lipophilicity. 
 
Delivery 
The main problems that limit the clinical use of cisplatin include acquired resistance and serious 
side effects such as neurotoxicity and nephrotoxicity. These shortcomings are closely related to the 
lack of tumour selectivity of cisplatin. So, in the past two decades, several strategies have been used 
to try to include targeting groups such as small ligands and drug delivery systems in platinum-based 
compounds. Huang et al. [39,40] introduced a series of cisplatin-like compounds with 
monoaminophosphonate ester as the carrier ligand and chloride as the leaving group (C21, Figure 
8). Because alkaline phosphatase is overexpressed in the extracellular space of specific tumour cells 
such as ovarian and hepatic carcinoma cells, introduction of a phosphate group for targeted delivery 
appeared to be a reasonable strategy to increase solubility and to enhance transport through the cell 
membrane. Some phosphate groups also exhibit high affinity for calcium ions and have been used 
to design targeted drugs for testament of bone cancer. 
Another approach to attach the PtCl2 scaffold to the target DNA was proposed by Wisnovsky et al. 
[70]. In their approach, C22 (Figure 8), an analogue of cisplatin, was delivered to mitochondria of 
human cells by means of mitochondria-penetrating peptide linked to the Pt(NH3)2 fragment by a β-
diketonate acting as a leaving group. Mitochondria-penetrating peptides are short, cell-permeable 
peptide sequences, comprising alternating lipophilic and cationic residues that exhibit minimal 
toxicity towards human cells. C22 induces apoptosis without damaging nuclear DNA, confirming 
that mitochondrial DNA damage is sufficient to mediate the activity of a platinum-based 
chemotherapeutic. This study was the first to demonstrate specific delivery of a platinum drug to 




Active molecules as N-ligands 
Novakova et al. [71] synthesized the cisplatin-like complex C23 (Figure 9), in which the two 
ammonia ligands are replaced by the cyclin-dependent kinase inhibitor bohemine. This compound 
exhibited a unique anticancer profile which may be associated with some features of the damaged 
DNA and/or its cellular processing; the mechanism of action was different from that of cisplatin 
because of (1) the slower rate of the initial binding to DNA, (2) the lower efficiency to form 
bifunctional adducts, (3) the reduced bending of the longitudinal DNA axis induced by the major 
1,2-GG intrastrand cross-link, (4) the reduced affinity of high-mobility group proteins for the major 
adduct, (5) the enhanced efficiency of the DNA adducts to block DNA polymerization and to inhibit 
transcriptional activity of human RNA polymerase II and RNA transcription and (6) the slower rate 
of the reaction with glutathione. The same research group [46] studied the anticancer potential of 
Pt(II) complexes involving disubstituted and trisubstituted derivatives of the plant hormone kinetin 
as carrier ligands (C24, Figure 9). The complexes were able to circumvent cisplatin resistance in 
A2780cisR cells while additionally being significantly more cytotoxic to A2780 cells than cisplatin; 
this was mainly ascribed to hydrolytic stability and interactions with glutathione and guanosine 
monophosphate. 
Jain et al. [72] studied the trinuclear Ru(III)/Pt(II) metal complex C25 (Figure 9), in which the two 
ammonia molecules of cisplatin were replaced by two amine Ru(III) metalloligands, similar to what 
is done in the active anticancer agent NAMI-A, which is currently in clinical trials as an 
antimetastatic prodrug. The trinuclear complex is strikingly more effective than cisplatin and 
NAMI-A in the binding of RNA as well as in the inhibition of primer DNA synthesis. 
Hui, Zhang and Chen [73] synthesized a series of dichloridoplatinum(II) complexes of 
podophyllotoxin. Among these, cis-[4α-O-(2″,3″-diaminopropanoyl)podophyllotoxin]dichloride 
platinum(II) (C26, Figure 9) displayed the most potent cytotoxicity, with a sub-micromolar IC50 
value. This compound induces cell cycle arrest in the G2/M phase and inhibits the formation of 
microtubules in HeLa cells. Furthermore, it exhibits potent DNA cleavage capabilities. 
Neves et al. [52] studied a series of chloride Pt(II) complexes of 2-hydroxy-3-(aminomethyl)-1,4-
naphthoquinone Mannich bases (C27, Figure 9) exhibiting high cytotoxicity towards cancer cell 
lines. Natural and synthetic quinone derivatives have been widely investigated for cancer therapy 
because of their capability to form reactive oxygen species (ROS) in vivo. The PtCl2 fragment 
substantially affects the chemical and biophysical properties of quinone ligands, leading to an 
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improvement of their DNA-binding properties and the generation compounds that cleave DNA and 
catalytically inhibit topoisomerase I. 
Another approach to conjugate the effect of cisplatin with the inhibition of topoisomerase was 
proposed by Dallavalle’s research group [48]; it involved two hybrid agents formed by 7-
oxyiminomethylcamptothecin derivatives and diaminedichloridoplatinum(II) complex C28 (Figure 
9). These compounds contain camptothecin, an inhibitor of topoisomerase I, and the active principal 
of irinotecan. The compounds exhibited growth-inhibitory activity against a panel of human tumour 
cell lines, including sublines resistant to topotecan and platinum compounds. This supported the 
interpretation that the diaminedichloridoplatinum(II) complex conjugated with the camptothecin 
could result in a new synergic class of effective antitumour compounds. 
Bérubé’s group [74] designed and prepared new combi-molecules using 17-acetyltestosterone and 
amino acid Pt(II) complexes linked at the 7a-position (C29, Figure 10) to target and to improve the 
antiproliferative activity of Pt(II)-based chemotherapy against prostate cancer cells. 
 
Stereochemistry 
As in many cases the carrier amino ligand is an asymmetrical molecule, stereochemistry could 
influence the activity. Recently, Arnesano et al. [75] reviewed the effect of chirality in platinum 
drugs. It is well known that trans-(R,R)-1,2-diaminocyclohexane-containing platinum complexes 
exhibit better performance than the corresponding trans-(S,S)-1,2-diaminocyclohexane- and cis-
(R,S)-1,2-diaminocyclohexane-containing platinum complexes [38]; this has been related to its flat 
shape that favours the first approach to DNA. Some articles have described this aspect; for example, 
Liu et al. [76] reported the 4S,5S isomer of C30 (Figure 10) exhibits superior antitumour activity 
and less toxicity in comparison with the 4R,5R optical isomer as well as the parent heptaplatin 
(Figure 1). 
 
2.1.3. Cationic monofunctional complexes 
Cationic monofunctional Pt(II)-based anticancer agents with the general formula cis-[Pt(NH3)2(N-
donor)Cl]+ (C31a and C31b, Figure 11, are two examples) have received attention because of their 
unique mode of action, distinctive anticancer spectrum and promising antitumour activity both in 
vitro and in vivo. Studies of the mechanism revealed that monofunctional platinum compounds bind 
well to DNA and effectively inhibit transcription. Understanding the mechanism of action of novel 
monofunctional platinum compounds through rational drug design will aid in the further 
development of active agents. Wang et al. [77] synthesized and evaluated a monofunctional 
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platinum-based anticancer agent containing a bulky salicylanilide moiety, C31c. The compound 
bound to DNA as cisplatin, but did not block RNA polymerase II–mediated transcription as 
strongly as cisplatin, indicating that once the compound formed Pt-DNA lesions, the salicylanilide 
group was more easily recognized and removed. This study not only enriches the family of 
monofunctional platinum-based anticancer agents but the findings could also help in the design of 
more potent monofunctional platinum complexes. 
Wang et al. [78] also developed cationic monofunctional Pt(II)-based anticancer agents (C32, 
Figure 11) in which the N-donor is a nicotinamide-like inhibitor of poly(ADP-ribose) polymerase 1; 
in clinical trials they were promising against cancer and other diseases. The complexes, in particular 
C32c, are able to enter cancer cells efficiently, to bind DNA well, and to block the cell cycle at 
G2/M phase, indicating that the conjugation of platinum with poly(ADP-ribose) polymerase 1 
inhibitors could be a valid strategy to obtain more potent anticancer agents with improved 
biological activities with two distinct mechanisms of action. 
 
2.1.4. Trans platinum complexes 
The trans isomer of cisplatin is inactive and, because of this lack of activity, all trans platinum 
complexes were assumed to be ineffective as antitumour agents. Now, it is recognized that the 
replacement of NH3 with other amino ligands (L or L′) in the trans position within the structure, 
trans-[PtCl2(L)(L′)], can afford cytotoxicity in the micromolar range. For example, C33 (Figure 
11), named ampyplatin [41], forms DNA adducts similar to those of monofunctional Pt(II) 
complexes, such as C31a. Legin et al. [79] compared the activity of a series of cis and trans Pt(II) 
complexes in which ligands are guanidines; the cytotoxicity of trans-configured complexes is, in 
some cases, comparable to or higher than that of the cis congeners.  
C34 (Figure 11), recently synthesized and studied by Icsel et al. [80,81], is a trans-dichlorido Pt(II) 
complex in which the two amine carrier ligands are 2-(2-hydroxyethyl)pyridine. This trans complex 
showed higher anticancer activity against different cancer cell lines than transplatin, cisplatin, 
carboplatin and oxaliplatin.  
Fabijańska et al. [82] described the synthesis of trans-bis(3-aminoflavone)dichloridoplatinum(II) 
(C35, Figure 11) as a potential anticancer compound, and evaluated its biological behaviour. C35 
demonstrated a significant cytotoxic effect against human and murine cancer cell lines as well as 
weaker toxicity towards healthy cells (human peripheral blood lymphocytes) in comparison with 
cisplatin. The proapoptotic activity of this trans complex is markedly higher than that of cisplatin, 
suggesting that it may have an antitumour specificity different from that of cisplatin. 
15 
 
Herrera et al. [83] proposed a series of Pt(II) complexes to obtain more potent and selective 
metallodrugs (C36, C37, Figure 12); they bear aliphatic amines and ligands with specific DNA-
targeting properties. The group developed six new trans-dichlorido platinum-based molecules 
containing dimethylamine or isopropylamine in the trans position with respect to a naphthalimide-
based ligand. They contain a covalent DNA binder (trans-dichlorido platinum) connected through 
an aliphatic spacer to the intercalator naphthalimide moiety. The synergistic combination of the 
DNA binder and the DNA intercalator enhanced the antitumour activity of these trans platinum 
complexes. The distance of the naphthalimide to the metal centre was determinant for their 
cytotoxic activity. C36a and C36c showed the best cytotoxicity in both cisplatin-resistant and non-
resistant cancer cell lines. Although C36c was the most active, C36a showed the best selectivity 
between cancer and normal cells. From cytotoxicity and DNA-interaction studies, these complexes 
seem to act through a combination of platination and naphthalimide-DNA interaction. Moreover, 
the subcellular uptake studies suggested that, in addition to DNA, these complexes might also 
interact with other cellular targets. 
Del Solar et al. [84] reported the first study on the cytotoxic effect of sulfonamide platinum 
complexes; they synthesized a series of trans-N-sulfonamide Pt(II) complexes studied as 
antiproliferative agents in human solid tumours cells. The best compound was C38 (Figure 12), 
formed by the trans-dichloride, dansyl sulfonamide and dimethyl sulfoxide (DMSO) at the platinum 
centre. Fluorescent cell assays showed that the final target is the cell nucleus. 
Other examples of great interest as unconventional metallodrugs are the iodide analogues of 
cisplatin. Iodide complexes have not received great attention as pharmacological agents because of 
their low activity in aqueous solution and also because cis-[PtI2(NH3)2] was inactive as an 
anticancer agent [85]. There are only a few reports in the literature indicating a special reactivity of 
iodide platinum complexes towards important biological targets; for example, compounds C16 
(Figure 7) [37]. In contrast, trans-iodide complexes of Pt(II) afforded higher cytotoxicity values, 
exhibiting reactivity different from that of their cis counterparts. Moreover, both trans- and cis-type 
complexes bind to DNA models with retention of the amine spectator ligand. The lower reactivity 
of the trans-iodide compounds towards peptides might help their reactivity towards DNA and also 
their uptake into the cell. Examples of trans-iodide platinum complexes (C39, Figure 12) exhibiting 
biological activity have been reported by Parro et al. [86]. 
 
2.2. Palladium(II) complexes 
16 
 
The Pt(II) and Pd(II) coordination modes and chemical properties are quite similar, and as a 
consequence, their complexes are expected to show similar behaviour. This is the reason why Pd(II) 
has received much attention as an alternative to platinum in the search of new cisplatin analogues 
for antitumour treatments. However, Pd(II) complexes are somewhat less stable, from both a 
thermodynamic and a kinetic point of view, than the corresponding platinum analogues and are 
about 105 times more reactive [12,87]. As a consequence, palladium-based drugs can undergo a 
rapid hydrolysis before they reach the target; this results in both a low antitumour activity or even 
inactivity and toxicity. In addition, their relative lability and their tendency to predominantly form 
trans isomers might trigger cis-trans isomerization, thus leading, at least in the beginning, to 
inactive species. To overcome these drawbacks—that is, to reduce the reactivity of the Pd(II) ion—
the carrier ligands should be bulky and feature strongly coordinating donor atoms such as nitrogen, 
sulfur, or phosphorus, preferably provided by a chelating ligand. In this case, solid-state structure 
characterization also helps to evidence strains [18,88], the trans effect [18], and intermolecular 
interactions holding together the crystal [89,90]. 
Further structural/electronic/energetic information can be obtained through modelling techniques, 
applied to studying the metal complexes as, for example, in [51], as well as their adducts with the 
biological target [89]. 
A valid strategy to obtain effective Pd(II) complexes is to stabilize the N–Pd interaction with the 
amine carrier ligand by use of secondary chelating bulky diamines to decrease the excessive 
reactivity. The use of sterically hindered amines lowers the reactivity and increases the lipophilicity 
of the complexes, making them suitable to enter cells. For example, Lj et al. [91] synthesized a 
series of Pd(II) dichlorido complexes in which the diamine carrier ligands were diethyl, dipropyl, 
dibutyl and dipentyl esters of (S,S)-ethylenediamine-N,N′-bis(2,2′-bis(4-hydroxybenzyl))acetic acid, 
a double tyrosine (C40, Figure 13). All compounds tested showed dose-dependent inhibition of cell 
viability for two different cell lines (MDA-MB-231 human breast cancer and A549 human lung 
cancer cell lines) and human chronic lymphocytic leukaemia cells. The most active complex was 
C40d, in which two pentyl groups are present as ester alkyl chains, confirming the crucial role of 
lipophilicity in cytotoxicity. Tanaka et al. [92] synthesized a glycoconjugate cis-PdCl2 complex 
(C41, Figure 13) able to overcome cross-resistance to cisplatin both in vitro and in vivo. 
In the same field, Matović et al. [89] obtained stable and biologically active Pd(II) complexes using 
an O,N,N,O tetradentate ligand in which, two N-donors are deprotonated secondary amides acting 
as a carrier group and two oxygen atoms, belonging to two carboxylate anions, act as a leaving 
group. The anionic complexes C42a and C42b, with malamido-N,N′-diacetic acid and oxamido-
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N,N′-di-3-propionic acid (Figure 13), exhibited high activity on several tumour cells, thus revealing 
significant antitumour properties and less resistance of tumour cells in vitro than to cisplatin. From 
crystal structure and density functional theory calculations, the interaction with DNA is initially 
hydrogen bond driven, then nucleic acid bases bind the metal centre in an associative SN2 manner 
replacing the first and then the second carboxylate group and producing an intrastrand covalent 
interaction. 
The use of soft ligands can be a valid strategy to improve stability and reduce the reactivity of 
palladium complexes. Motswainyana et al. [18] reported a series iminophosphine-chelating Pd(II) 
and Pt(II) complexes The coordination geometry around the palladium and platinum atoms in the 
respective structures was distorted square planar at the metal centres. The complexes were 
evaluated in vitro for their cytotoxic activity against human breast cancer (MCF-7) and human 
colon cancer (HT-29) cells. They exhibited growth-inhibitory activities and selectivity that were 
superior to those of cisplatin. In particular, Pd(II) complexes C43 (Figure 13) exhibited twice the 
activity of the Pt(II) complexes.  
A monofunctional coumarin-based Pd(II) system having micromolar and sub-micromolar activity 
was reported by Ilić et al. [90] (C44, Figure 13). The Pd(II) ion is coordinated by a tridentate 
coumarin derivative 3-(1-(2-hydroxyethylamino)ethylidene)chroman-2,4–dione and by a chloride 
anion; the complex decreased viability of L929 mouse fibrosarcoma, U251 human glioma and B16 
mouse melanoma cell lines in a dose-dependent manner, whereas the ligand exhibited no significant 
cytotoxicity. The cytotoxic effect of the complex was comparable to that of cisplatin; it is mediated 
by apoptosis associated with oxidative stress, mitochondrial depolarization and caspase activation. 
All these examples indicate that suitable Pd(II) complexes can be potential candidates for anticancer 
therapy. 
 
3. Platinum(IV) complexes 
Some problems linked to anticancer Pt(II)-based compounds, such as unselective binding to off-
target biomolecules, side effects, and the need for intravenous administration, can be overcome by 
the use of Pt(IV) octahedral complexes which feature two additional binding sites. The relative 
kinetic inertness which characterizes the latter in comparison with the Pt(II) square planar 
congeners makes them suitable for oral administration, decreasing both the possibility of side 
reactions in the bloodstream (where it is estimated that about 90% of the administered cisplatin is 
deactivated) and undesirable side effects. They have the potential to be used as prodrugs based on 
an activation by reduction mechanism (hopefully intracellularly) providing the corresponding 
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square planar Pt(II) active complex. So far, four Pt(IV) complexes—namely, tetraplatin, iproplatin, 
satraplatin and LA-12 (Figure 3; for their solid-state structures, see [93-97]), have showed 
promising anticancer activity, but currently none of them have been approved for clinical use [98]. 
Studies of tetraplatin (tetrachlorido(trans-1,2-diaminocyclohexane)platinum(IV)) were abandoned 
because of severe neurotoxicity, whereas iproplatin 
(dichloridodihydroxidobis(isopropylamine)platinum(IV)) demonstrated lower activity than 
carboplatin and cisplatin. Satraplatin 
(bis(acetato)amminedichlorido(cyclohexylamine)platinum(IV)) was the first orally administered 
Pt(IV) complex with documented efficacy and acceptable safety in patients with hormone-
refractory prostate cancer and small-cell lung cancer. Despite the positive outcome after completion 
of the Satraplatin and Prednisone Against Refractory Cancer (SPARC) phase III clinical trials, 
satraplatin was not approved by the FDA because it did not show a convincing benefit in terms of 
overall survival. However, clinical studies with satraplatin are still ongoing [99]. 
The reduction process, which occurs before the metal complex reaches DNA, is (generally) 
accompanied by the release of the axial ligands. As a consequence, the nature of the latter play a 
crucial role in determining the redox properties of the Pt(IV) species and hence the reactivity: for 
complexes featuring chloride ligands in equatorial positions, redox potentials and reduction rates 
correlate [17,100,101]. The order of the reaction rate with respect to the axial ligands is as follows: 
chloride ≈ trifluoroacetate > carboxylate > hydroxide [101,102]. Consistently, cisplatin derivatives 
with trifluoroacetate ligands in axial positions undergo Pt(IV)→Pt(II) reduction more rapidly than 
the corresponding species with acetate donors, thus evidencing that the electron-withdrawing 
character of the axial ligands influences the reduction rate [103]. In addition, Pt(IV) complexes 
having trifluoroacetate and dichloroacetate as axial ligands can be unstable at neutral pH and 
undergo a rapid hydrolysis (thus affecting their physicochemical and pharmacological properties), 
whereas the corresponding complexes with monochloroacetato or acetato ligands are stable [102]. 
Incidentally, there are no significant differences in the metal coordination sphere of the 
corresponding complexes with dichloroacetate and monochloroacetato as determined by single-
crystal X-ray diffraction [102]. 
Finally, the nature of axial ligands affects the balance between hydrophilicity [104] and lipophilicity 
[105,106] of the complex, thus influencing solubility, oral absorption [107] and cellular 
accumulation. 
 
3.1. Axial leaving group 
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Zanellato et al. [106] discussed the biological properties of a series of cisplatin-based Pt(IV) 
prodrug candidates—namely, trans,cis,cis-[Pt(carboxylate)2Cl2(NH3)2], where carboxylate was 
acetate, butanoate, hexanoate, or octanoate (C45, Figure 14). The complexes exhibited a large range 
of lipophilicity and are stable from pH 1 to 9, making them suitable for oral administration. The 
transformation into their active Pt(II) metabolites was demonstrated in the presence of ascorbic 
acid, with pseudo-first order kinetics, the half-time of which smoothly decreased as the chain length 
of the carboxylic acid increased. As expected, the antiproliferative potency, tested on a large panel 
of human cancer cell lines, increased with the chain length; C45c and C45d were more active than 
cisplatin on all cell lines tested by about one or two orders of magnitude, respectively. Both 
complexes retained their activity also on a cisplatin-resistant cell line and exhibited a progressive 
increase of the selectivity compared with selectivity towards non-tumour cells. It is possible to 
overcome oxaliplatin chemoresistance in colorectal cancer cells by use of trans,cis,cis-
bis(benzoato)dichloride[(R,R)-1,2-diaminocyclohexane)]platinum(IV) (C46, Figure 14) bearing 
1,2-diaminocyclohexane as the carrier the ligand; C46 contains the same diamine present in 
oxaliplatin inserted in an octahedral Pt(IV) scaffold, with high lipophilicity conferred by the two 
benzoate axial ligands [105]. 
A great contribution to the study of the effect of the axial leaving group on Pt(IV) complexes has 
come from Austria thanks to an extended collaboration between chemical and medical academic 
and non-academic groups [99,108]. They reported a convenient synthetic procedure for the 
preparation of novel bis(dicarboxylato)platinum(IV) complexes and the modulation of their 
physicochemical properties of interest (e.g. solubility, lipophilicity and redox behaviour). The set of 
compounds (C47, Figure 14) tested covers a broad range of in vitro cytotoxicity (IC50 values from 
0.009 μM to more than 500 μM) in various cancer cell lines. Most of the compounds are active in 
vitro, and the results of experiments in vivo are agree somewhat with the results of the cell culture 
experiments. In contrast, the data from cell culture experiments were not at all predictive for the in 
vivo activity after oral gavage. The mechanisms leading to this discrepancy between in vivo and 
cell culture experiments are so far speculative. One explanation might be rapid metabolization 
indicated by serum analysis, which showed that as early as 2 h after oral treatment the administered 
drugs had been completely metabolized and/or bound to proteins in serum. In addition, cytotoxicity 
tests conducted solely with human cancer cell lines do not consider the complex interactions 
between various tissue types and their impact on the pharmacokinetics and pharmacodynamics of 
the tested compounds. Further investigations of the role and activity of diverse drug metabolites are 
ongoing and will help to better understand the fate of anticancer drugs in vivo. Moreover, such 
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detailed knowledge can improve the prediction of in vivo anticancer activity, allowing the selection 
of the best drug candidates for further (pre)clinical development. 
 
3.2. Conjugation with bioactive molecules 
To improve the therapeutic effect of Pt(IV) prodrugs, a drug with a complementary mode of action 
can be coordinated (generally as a carboxylate derivative) to the Pt(IV) core. The final compound 
can operate on multiple targets with greater potency (provided the two activities are synergistic) and 
with fewer side effects than a single-target drug; a bifunctional or hybrid or dual-threat 
pharmaceutical agent as well as a combi-molecule can be conjugated. Gabano et al. [109] critically 
analysed the activity of Pt(IV) prodrugs conjugated with several fragments: with oestrogens, where 
binding to the oestrogen receptor increases the sensitivity to cisplatin of MCF-7 breast tumour cells; 
with dichloroacetate, which induces mitochondrial apoptosis; with paclitaxel (a cytotoxic analogue 
of taxol); with ethacrynic acid, which inhibits glutathione S-transferase, an enzyme involved in 
cisplatin resistance; and with valproic acid, a well-known antiepileptic drug that acts via inhibition 
of histone deacetylase. All these examples of combi-molecules have remarkable activity with 
respect to cisplatin, but the synergism with the active biomolecule was reported only in the case of 
paclitaxel and dichloroacetate conjugates, for which the activities of the combi-molecules were 
higher than those of an equimolar combination of cisplatin and bioactive compound. These 
contradictory results represent an example of a false positive because some bioactive ligands, such 
as valproic acid, act at millimolar concentrations, wheras cisplatin is administered in the 
micromolar range. Conversely, the oestrogens have a beneficial effect at the nanomolar level and 
can be toxic at the micromolar level. The increase of the effect of such combi-molecules with 
respect to cisplatin could be the result of a better cellular accumulation due only to the lipophilicity 
conferred by the bioactive ligand.  
More recently, Ma et al. [110], reported a Pt(IV) prodrug derived from cisplatin with two dichloro 
chalcone derivatives acting as a p53 activator (C48, Figure 15). This single anticancer agent, called 
“chalcoplatin” by the authors, resulted in synergistically improved cytotoxicity in p53 wild-type but 
not p53-null human cancer cells. A mechanistic investigation was conducted. The prodrug 
effectively entered cancer cells and arrested the cell cycle at the S and G2/M phases, distinctively 
different from cisplatin. Chalcoplatin (C48) significantly induced p53 activation as well as the 
subsequent apoptosis pathways. This unique mode of action renders it remarkably cytotoxic and 
makes this compound among the first examples of a Pt(IV) prodrug that directly interacts with the 
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downstream pathway after the formation of Pt–DNA lesions. In this case, a synergistic mechanism 
between Pt(II) and chalcone was observed. 
Cyclooxygenase (COX) is an enzyme involved in tumorigenesis and it is associated with tumour 
cell resistance to platinum-based antitumour drugs. Hey-Hawkins et al. [111] conjugated the 
NSAIDs indomethacin and ibuprofen with both Pt(II) and Pt(IV) analogues to explore the 
synergistic effects observed in combination treatments. The Pt(II) complexes revealed cytotoxic 
activities similar to the cytotoxic activity of cisplatin. In contrast, the Pt(IV) complexes C49a, 
C49b, C50a and C50b (Figure 15) exhibited remarkably higher cytotoxicity in all tumour cell lines 
tested and were able to completely overcome cisplatin-related resistance. Although the 
indomethacin conjugates were potent COX inhibitors, they appeared to execute their cytotoxic 
action via COX-independent mechanisms. The activities were similar in all cell lines independently 
of COX-2 expression and the COX potency of the conjugate or the respective NSAID. However, 
the potent Pt(IV) conjugates exhibited increased accumulation in the cells relative to that of 
cisplatin, probably resulting from their higher lipophilicity and kinetic inertness, thus leading to a 
clearly enhanced cytotoxicity. Investigations of this kind using conjugates are of fundamental 
importance to demonstrate that the observations from combination treatments are not directly 
transferable to dual-acting prodrugs and that the conjugates are important tools for the elucidation 
of the direct influence of COX inhibitors on platinum drugs in cells. 
These few examples underline that the main difficulty in the interpretation of the activity of 
bifunctional Pt(IV) drugs is to determine whether synergism occurs or whether the increase of the 
activity is determined only by the improved pharmacokinetic properties of the complex. 
 
3.3. Other platinum(IV) systems 
Lorenzo et al. [104] synthesized and studied a series of Pt(IV) complexes having 1,2-
bis(aminomethyl)carbobicyclic or oxabicyclic carrier ligands (C51, Figure 16), bearing chloride 
and/or hydroxide ligands in the axial position and chloride or malonate ligands in the equatorial 
position as labile ligands. The introduction of bicyclic amines as carrier ligands allows one to 
improve the lipophilicity while limiting the increase of steric hindrance. The lipophilicity plays a 
crucial role in determining the cytotoxicity; in fact, the more active complex in vitro is C51a, 
formed by bicyclo[2.2.2]octane with amine ligands and four chloride ions as labile groups. 
Lipophilicity improves pharmacodynamic properties, but one of the major problems of platinum-
based drugs is their poor pharmacokinetics owing to their very low water solubility. Clinically, 
platinum drugs are usually administered as a suspension in a physiological saline solution. To 
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improve the water solubility of the complexes, Lorenzo et al. worked at the level of the labile 
ligands, which are the first ligands exchanged during the absorption and distribution process of the 
drug. They introduced two hydroxide and a malonate bidentate ligands; in this way, C51b exhibited 
activity similar to that of cisplatin, with hydrophilic properties suitable for oral administration. 
Another problem related to Pt(IV) compounds is the rapid and premature reduction in vivo; 
consequently, selection of a suitable ligand sphere to ensure appropriate activation kinetics is 
essential for clinical success. In line with these requirements, Varbanov et al. [100] explored the 
bischelate and trischelate diaminebis(dicarboxylato)platinum(IV) sphere of C52 (Figure 16), which 
is believed to be optimal from hydrolysis kinetics considerations. Nine novel complexes were 
synthesized and studied; their cytotoxicity in vitro was mainly dependent on the amine carrier 
ligands, whereas the 1,2-diaminocyclohexane-containing compounds were the most potent species 
in all cell lines tested, with IC50 values comparable to or superior to those of carboplatin. 
Surprisingly, the increase of the lipophilicity through the use of different carboxylate ligands had 
only a minor effect on the cytotoxicity within the series. The pronounced anticancer and especially 
antileukaemic activity combined with a low systemic toxicity observed in animal experiments 
indicates that C52 might be a promising candidate for further preclinical development. 
 
4. Platinum(II) and palladium(II) as a structural moiety for non-covalent interaction with 
DNA 
DNA is an anionic polyelectrolyte that plays a fundamental role in the storage and expression of 
genetic information in a cell. The study of interaction of DNA with cationic metal complexes and 
the cytotoxic effects of such interactions has been a very active area during recent decades. These 
metal complexes bind to DNA through a series of binding modes, among them the main one is the 
covalent binding discussed in Section 2. However, metal systems can interact with DNA also by 
non-covalent interactions, the main ones being (1) electrostatic interactions of positively charged 
metal complexes with negatively charged phosphate groups of DNA, (2) groove binding, in which 
molecules bind in the DNA helix grooves involving hydrogen bonds and van der Waals 
interactions, and (3) π-stacking interactions, commonly observed between two planar aromatic 
groups. Among them, the most investigated is the latter, giving rise to the intercalating binding 
mode; it is the non-covalent π-stacking interaction resulting from the insertion of a planar aromatic 
ring, belonging to a ligand, between base pairs of the DNA double helix [112-116]. This way to 
bind DNA was first proposed by Lerman [117] to explain the strong affinity for DNA of some 
heterocyclic aromatic dyes, such as the acridines. In this context, the seminal work of Bond et al. 
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[118], which firstly showed, thanks to X-ray fibre diffraction measurements, structural evidence for 
interactions of this kind for the 2-hydroxyethanethiolato(2,2′,2′-terpyridine)platinum(II) complex, 
must be mentioned. Both the presence of a planar ligand and the coordination geometry of the metal 
ion are important in determining the intercalating propensity of a given metal complex towards 
DNA. In addition, it can be postulated that the ability to intercalate depends on the extension of the 
aromatic region able to provide π-stacking interactions: the larger is the aromatic surface, the higher 
is the DNA binding affinity. Several studies seem to support this hypothesis [119,120], even if 
subtle hints [120] and different trends [121] make further investigations mandatory. As a 
consequence, a vast collection of different aromatic groups have been used to try to guarantee good 
intercalation properties for platinum- and palladium-based metal complexes, such as pyridine 
[113,116,122], bipyridine [122,123], terpyridine [124], phenanthroline [125,126], 8-
hydroxyquinoline [127,128] and naphthalene [129], as well as several aromatic ligands bearing 
sulfur donor moieties, such as thiosemicarbazone, mainly for the palladium atom [130-132]. 
In this context, results from molecular and crystal structure determinations can offer valuable 
information about the overall shape of the metal complexes [130,123,132,133] (a planar 
arrangement would favour the intercalative interaction with DNA [113,114,127,131,133]) and the 
propensity of the aromatic moieties to be involved in π-stacking interactions with the neighbouring 
species in the crystal lattice [114,120,125,126,128]. 
The intercalation stabilizes, lengthens, stiffens, and unwinds the DNA double helix, and the degree 
of unwinding varies depending on the specific intercalator. The ethidium cation unwinds DNA by 
about 26°, whereas proflavine unwinds it by about 17°. These structural modifications of DNA can 
lead to functional modifications, or inhibition of transcription and replication or suppression of the 
DNA repair processes. All these effects make intercalators potent mutagens. Intercalative 
interactions between DNA duplexes and planar polycyclic aromatic organic intercalators, such as 
ethidium bromide (EB), acridine and its derivatives and benzo[a]pyrene have been thoroughly 
studied. Studies of bulky intercalators are quite rare.  
Generally, the metal complexes that undergo intercalation with DNA can be divided in two main 
classes. For relatively inert coordinatively saturated square-planar Pt(II) and Pd(II) complexes with 
aromatic ligands, intercalation into DNA mainly involves the aromatic ligands. Metal complexes 
containing σ-bonded ligands having aromatic side arms for use as intercalators can be described as 
dual-function complexes: the aromatic side arms of the ligands can intercalate between DNA bases, 
whereas the metal coordinates directly to a DNA base. 
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Some recent examples of metal complexes in which the metal cation behaves as a structural moiety 
on binding with DNA, in the case of non-covalent interactions, are reported here for both Pt(II) and 
Pd(II) centres.  
 
4.1. Platinum(II) complexes 
Despite the large number of Pt(II) complexes reported with 8-hydroxyquinoline and its derivatives, 
the mechanism of their anticancer activity remains unknown. Qin et al. [127] synthesized two Pt(II) 
complexes, (C53 and C54, Figure 17) in which 8-hydroxyquinoline and 8-hydroxy-2-
methylquinoline are present as ligands. Both complexes are very stable in solution and exhibited 
high cytotoxicity towards a number of human tumours but low cytotoxicity towards normal HL-
7702 cells. Qin et al studied the cell cycle together with the apoptosis-inducing effect of the 
complexes; a number of crucial triggers in cell apoptotic pathways were also evaluated. Interactions 
of DNA with C53 and C54 were investigated, and the intercalation binding mode of these 
complexes, due to the planar aromatic structure of the corresponding quinolinol ligands, with DNA 
was demonstrated.  
Pages et al. [120] and Garbutcheon-Singh et al. [125] synthesized numerous active complexes with 
the general formula [Pt(IL)AL)]
2+, where IL is an aromatic intercalating ligand and AL is an ancillary 
ligand. The intercalating ligands included 1,10-phenanthroline derivatives and dipyridoquinoxaline 
variants, whereas the ancillary ligands were the R,R or S,S isomers of 1,2-diaminocyclohexane or 
1,2-diaminocyclopentane. They used different IL and AL combinations to modulate the chemical 
properties of the complexes with the aim of correlating the DNA binding affinity with the 
cytotoxicity of these complexes. As an example, C55 (Figure 17) had much higher binding affinity 
than C56 (Figure 17); this was explained by the larger aromatic surface area of dipyridoquinoxaline 
resulting in stronger π-stacking interactions between the ligand and the DNA base pairs. However, 
when the cytotoxicity was determined in the L1210 murine leukaemia cell line, all the 
dipyridoquinoxaline derivative–incorporating complexes were less active than those containing 
1,10-phenanthroline. These results suggested that the contribution of the ancillary ligand should 
also be considered for the DNA binding of these complexes and thus for their cytotoxicity. 
Special attention has been given recently to metal complexes with biphosphine ligands as potential 
therapeutic agents. Phosphine ligands in place of amines have been successfully used in gold-
containing complexes used as therapeutic agents [134-137,138]. In this context Jamshidi et al. [112] 
synthesized three cationic platinum complexes containing bis(diphenylphosphino)ethane as a non-
leaving carrier ligand. They investigated both the DNA binding properties and the anticancer 
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activity against Jurkat and MCF-7 cell lines, and all the complexes demonstrated a significantly 
higher level of anticancer activity compared with cisplatin. However, only C57 (Figure 17) was 
capable of stimulating significantly the activity of caspase 3 and of inducing programmed cell death 
in Jurkat cancer cells. The study suggested that the interaction between DNA and the platinum 
complexes occurred according to a mixed-binding mode where intercalation, electrostatic binding 
and coordination were involved. 
Zamora et al. [139] synthesized the steroidal 7-azaindole Pt(II) complexes C58 and C59 (Figure 17) 
with the aim of decreasing the main side effect associated with classic platinum-based anticancer 
compounds and of increasing the activity spectrum through more effective delivery of the drug to 
the desired target. They wanted to exploit the property of oestrogens to easily cross the cell 
membrane by passive diffusion and then to be bound by the oestrogen receptor in the cytoplasm and 
transferred to the nucleus. The biological potential of these stable compounds was evaluated 
towards the human breast cancer cells (T47D, cisplatin resistant) and epithelial ovarian carcinoma 
cells (A2780 and A2780cisR, acquired resistance to cisplatin). The results indicated great potential 
of these complexes to overcome cisplatin resistance and less toxicity towards normal human LLC-
PK1 renal cells than cisplatin.  
Platinum complexes bearing π-conjugated heterocyclic ligands such as terpyridine and its 
derivatives constitute a wide class of potential anticancer agents tested in recent years. Numerous 
examples of terpyridine-based platinum complexes have been reported in literature as efficient 
DNA intercalating units and active antitumour agents. In such systems, three nitrogen donor atoms 
are furnished by the terpyridine ligand, and the remaining fourth coordination position is quite 
variable. As an example of these systems, Zhang et al. [140] inserted a xanthine derivative such as 
caffeine in the fourth position of the square planar geometry of the Pt(II) ion, obtaining C60 (Figure 
17). The in vitro cytotoxicity of the complex was tested towards MCF-7, MDA-MB-231 and HT-29 
tumour cells, and the values obtained, in the submicromolar range, exceeded the activity of cisplatin 
in the same conditions. Moreover, Zhang et al. highlighted the C2 atom coordination for the 
xanthine ligand might be responsible of the higher biological potencies of C60 with respect to N5-
coordinated analogues. Banerjee et al. [114] inserted a 4-amino-1,8-naphthalimide derivative as the 
fourth ligand in a Pt(II) terpyridine system. The resulting bifunctional complex (C61, Figure 17) 
exhibited high DNA binding affinity together with good cellular toxicity, comparable to that 
observed for cisplatin. This intercalating complex was readily taken up by breast and cervical 
cancer cell lines, inducing apoptosis.  
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Two Pt(II) terpyridine systems can be combined together to form bis-intercalating complexes 
whereby the remaining fourth coordination position was used to produce a bridge linking the two 
platinum centres. The cytotoxicity of such bis-intercalating systems is higher than their 
corresponding mononuclear units. Harper and Aldrich-Wright [141] synthesized a series of 
dinuclear Pt(II) terpyridine complexes connected by different linkers with the aim of exploring the 
effect of the chain length, flexibility, charge and stabilities on the cytotoxicity. In general, it was 
difficult to determine a structure-activity relationship: subtle structural differences reflected in 
evident variations in cytotoxicity as well as similar cytotoxicity were observed for complexes with 
large structural variations. In such a series, complexes that had an aliphatic thiol linker were more 
cytotoxic than cisplatin towards A2780cisR cells, with C62 (Figure 18) being the most potent. 
Organometallic compounds based on platinum have not received great attention as potential 
anticancer drugs probably because attention has been mainly focused on cisplatin analogues. In this 
context, Vezzu et al. [122] synthesized a series of structurally diverse cyclometallated platinum 
complexes and evaluated their cytotoxicity towards NCI-H522, HCC827 and NCI-H1299 human 
lung cancer cells and RV1 human prostate cancer cells. They demonstrated that in the square planar 
complexes based on tridentate ligands examined, the dissociation of a labile monodentate ligand, 
such the chloride in C63 (Figure 18), was critical to obtain high cytotoxicity. C63 was more 
cytotoxic than cisplatin in the cell lines tested; moreover, it interacted with DNA, triggering 
apoptosis by activation of poly(ADP-ribose) polymerase via the caspase 7 pathway. Recently, 
Mohammadi et al. [116] reported the cyclometallated platinum complex C64 (Figure 18), based on 
deprotonated 2-phenylpyridine and a non-leaving lipophilic ligand, which exhibited higher 
cytotoxicity than cisplatin. The flexible chemical structure of C64 was determining for the 
anticancer activity of the complex, which also showed an interesting property from a therapeutic 
point of view as the lack of a necrotic effect. The interaction between the complex and DNA was 
demonstrated to occur through a mixed binding mode, comprising partial intercalation and groove 
binding. 
Gabano et al. [129] synthesized and evaluated two different platinum complexes with the formulas 
[PtCl2(NH3)(L)] (C65) and [PtCl2L2], where ligand L was the 2-aminonaphthalene group (Figure 
18). The cytotoxicity of the complexes was tested against the A2780 ovarian carcinoma, A2780Cp8 
cisplatin-resistant ovarian carcinoma and HCT 116 colon adenocarcinoma cell lines. C65 showed 
cytotoxicity as good as that of oxaliplatin with regard to HCT 116 cells; this remarkable result is 
probably due to the presence of the aminonaphthalene ring, which mimics the effects of the 
diaminocyclohexane moiety in oxaliplatin, enabling C65 to target tumours that respond poorly to 
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cisplatin. C65 acted as a strong intercalator inducing a negative twist in the structure of supercoiled 
DNA. Moreover, C65 was a strong binder of telomeric G-quadruplex structure, as it stacked on one 
external G-quartet and platinated the adenine residue close to it, with the result of cross-linking 
irreversibly the G-quadruplex structure.  
Icsel et al. [113] reported the synthesis and biological studies of two complexes (C66 and C67, 
Figure 18) based on substituted pyridine derivatives. The DNA binding studies revealed that the 
two complexes interacted with DNA; C66 interacted with DNA by a single intercalative 
mechanism, whereas C67 exhibited two types of interactions: intercalation and covalent binding. 
Both complexes have low cytotoxic activity against H1299 (human lung cancer) and 5RP7 (rat 
transformed fibroblast) cancer cell lines; however, C66 had IC50 values lower than those of 
transplatin and carboplatin. 
Most of the Pt(II) terpyridine systems exhibiting anticancer activity reported to date bind to DNA 
via intercalation. However, some Pt(II) terpyridine complexes can also bind via other non-
intercalative modes; Suntharalingam et al. [142] reported the synthesis and biological studies of 
C68 (Figure 18), in which the terpyridine ligand has two sterically demanding groups, with the aim 
of favouring a non-intercalative interaction with DNA. All data were consistent with C68 binding to 
the minor groove of DNA in a non-covalent manner. The almost planar structure of the complex fits 
in the minor groove of the DNA in a parallel manner with respect to the DNA backbone. C68 has a 
promising toxicity profile, with high potency towards the cancerous U2OS (human osteosarcoma) 
and SH-SY5Y (neuroblastoma) cell lines (comparable to cisplatin) and reduced toxicity towards the 
normal GM05757 human fibroblast cell line. Moreover, C68 selectively induced cell death in 
proliferating but not quiescent cells, and this is undoubtedly an attractive characteristic in terms of 
cancer therapy. 
 
4.2 Palladium(II) complexes 
Pd(II) derivatives have also been explored as an alternative to Pt(II)-based drugs. As already 
mentioned, Pd(II) displays similar chemistry to Pt(II) from many points of view; however, a 
significant difference between them is the high kinetic lability of Pd(II) complexes compared with 
Pt(II) complexes. Moreover, the better solubility of palladium complexes, compared with platinum 
complexes, seems to make palladium complexes more attractive. 
Thiosemicarbazone and its derivatives have been widely used as ligands for palladium because of 
their pharmacological properties. Prabhakaran et al. [132] reported the synthesis and biological 
studies of four thiosemicarbazone palladium complexes. The DNA binding studies revealed that all 
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the complexes interacted with calf thymus DNA (CT-DNA) via an intercalation mode. The 
cytotoxicity of the complexes was tested against the A549 (lung cancer) and HepG2 (liver cancer) 
cell lines, and the results evidenced that the activity of C69 and C70 (Figure 19) was higher in 
A549 cells than that of cisplatin; moreover, C69 had an IC50 value similar to that of cisplatin in 
HepG2 cells. The intracellular concentrations of the complexes were determined; the accumulation 
of C69 was higher than that of the other complexes, and this may contribute to the increased 
toxicity observed for this complex. Ramachandran et al. [130] described the synthesis, DNA and 
protein binding and in vitro toxicity of four Pd(II) complexes with 2-oxo-1,2-dihydroquinoline-3-
carbaldehyde 4N-substituted thiosemicarbazones (C71-C74, Figure 19). All the complexes bind to 
the DNA helix via intercalation, and the binding constants revealed that the cationic nature of C71 
enhanced the binding affinity for DNA. Moreover, all the complexes possessed potent free radical 
scavenging activity compared with the standard antioxidants. From cytotoxicity studies, all the 
complexes exhibited antitumour activities against human cervical cancer cells (HeLa), human skin 
cancer cells (A431), human liver carcinoma cells (HepG2), and human laryngeal epithelial 
carcinoma cells (Hep-2), without affecting tnormal cells. Moreover, they exhibited better 
cytotoxicity towards the HepG2 cancer cell line, with C71 showing an inhibitory activity about 
three times higher than that of cisplatin. Thiosemicarbazone derivatives were used by Hernández et 
al. [131] to synthesize a series of Pd(II) bischelate complexes that were evaluated for their cytotoxic 
activity against the H460 (human lung large cell carcinoma), M-14 (human amelanotic melanoma), 
DU145 (human prostate carcinoma), MCF-7 (human breast adenocarcinoma), HT-29 (human colon 
adenocarcinoma) and K562 (human chronic myelogenous leukaemia) cell lines. In general, all the 
complexes exhibited antiproliferative activity against all the human tumour cell lines investigated, 
with IC50 values below 10 µM; moreover, C75 and C76 (Figure 19) exhibited the greater cytotoxic 
activity, with IC50 values of 0.01-0.23 µM and 0.65-1.06 µM, respectively. The Pd(II) bischelate 
complexes act as intercalating agents between the pyrimidine and guanine bases of DNA of tumour 
cells, inducing conformational changes on the DNA double helix. In this context, the presence of 
the 3-hydroxy and 1-nitro substituent groups in the benzene and naphthalene aromatic rings of C75 
and C76, respectively, play an important role in the enhancement of the resulting antiproliferative 
activity. 
Ulukaya and co-workers [115,143-145] reported the anticancer activity of a Pd(II) saccharinate 
complex with terpyridine (C77, Figure 19). This complex strongly binds DNA by a dual function: 
by metal intercalation, interacting with the DNA helix through the insertion of the planar 
terpyridine ring between the DNA base pair, and by covalent binding. The results obtained with the 
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5RP7 and NIH/3T3 cell lines clearly demonstrated that C77 powerfully inhibited the growth of 
fibrosarcoma cells by inducing apoptosis. Moreover, cytotoxicity studies performed on the MCF-7 
and MDA-MB-231 human breast cancer cell lines revealed that C77 had a strong growth-inhibitory 
effect on MCF-7 cells rather than MDA-MB-231 cells. This Pd(II) complex induced apoptotic cell 
death through the caspase-dependent pathway in both cell lines. C77 was able to significantly 
reduce the growth of tumour cells in an in vivo model. C77 was also investigated in combination 
with niclosamide in breast cancer stem cells, highlighting the enhancement of the cytotoxic activity 
of both compounds [145]; in addition, it was tested in six different prostate cancer cell lines [146]. 
This complex seems important in terms of the cytotoxic effect of Pd(II) compounds on cancer stem 
cells that are thought to be responsible for both resistance to drugs and recurrence of the disease. 
Chu et al. [124] synthesized the terpyridine derivative–based complex C78 (Figure 19), introducing 
the piperidylethoxy group as a substituent in 4′-phenylterpyridine; the aim was to increase the 
solubility of the molecule and its interaction with DNA. The cytotoxicity of C78 was tested against 
eight different cell lines (HL-60, BGC-823, Bel-7402, KB, A549, HeLa, K562 and MCF-7), and the 
results indicated that the cytotoxicity was higher than that of cisplatin for all cell lines tested; in the 
Bel-7402 cancer cell line, C78 exhibited a sevenfold higher cytotoxicity than cisplatin. 
Gao et al. [126] studied the influence of the carbon chains bound to a Pd(II) metal centre on the 
DNA interactions and cytotoxic activities for a series of complexes with 1,10-phenanthroline as the 
auxiliary ligand and malonic acid derivatives as the main ligand (C79-C83, Figure 20). The DNA 
binding data indicated that the complexes interacted with the DNA helix by a strong stacking 
interaction between an aromatic group and the helix base pairs; the binding ability increased 
gradually as the length of the aliphatic chain became longer. All the complexes promoted the 
cleavage of pB322 DNA from supercoiled form I to the nicked form II, with C83 exhibiting the 
most effective DNA cleavage activity in comparison with the other complexes at the same 
concentrations. The in vitro growth-inhibitory effect of the complexes was evaluated in HeLa and 
KB cells; the results indicated that the cytotoxicity increased gradually as the length of the aliphatic 
chain became longer, with C83 showing cytotoxicity coefficients better than those of cisplatin for 
both cell lines. 
Wang et al. [146] synthesized a series of complexes in which the Pd(II) ion was coordinated by an 
aromatic N-containing ligand and 4-toluenesulfonyl-L-amino acid dianion. The cell growth 
inhibitory studies revealed that both the amino acid and the diamine have significant effects on 
cytotoxicity, with effects related to tumour cell type. C84 and C85 (Figure 20) exhibited 
cytotoxicity higher than that of cisplatin in the MCF-7 cell line.  
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As observed for Pt(II) compounds, also among Pd(II) complexes special attention has been paid to 
metallacycle complexes with nitrogen donor ligands. In fact, metallated species may bind to DNA 
by means of intercalative interactions, mainly when such complexes contain planar and stable 
aromatic structures. Albert et al. [147] evaluated a series of cyclopalladated primary amine 
complexes by means of a structure-activity relationship analysis of the inhibition of cell 
proliferation activity against a panel of human adenocarcinoma cell lines (A549 lung cancer, MDA-
MB231 and MCF7 breast cancer and HCT 116 colon cancer). C86 and C87 (Figure 20) exhibited 
the best antiproliferative activity and were more cytotoxic than cisplatin in all cell lines except 
A549. C86 and C87 were 14 and 19 times, respectively, more potent than cisplatin for the 
inhibition of the cisplatin-resistant HCT 116 human adenocarcinoma cell line. The complexes were 
not effective in removing the supercoils of plasmid DNA, pointing to a different mechanism of 
action or an alternative biomolecular target. The palladacycles C86 and C87 exercised their 
antiproliferative activity against A549 cells mainly through the induction of apoptosis.  
An example of dinuclear palladacycle complexes was reported by Karami et al. [133] by the 
synthesis and biological studies of two complexes (C88 and C89, Figure 20) in which the 
symmetric bidentate ligand 1,2-bis(diphenylphosphino)ethane bridges two identical cyclopalladate 
units. The DNA binding studies suggested that both complexes bind DNA by intercalation, with 
C89 binding more strongly than C88. The in vitro toxicity of the two complexes was evaluated 
against human cervix carcinoma (HeLa), colon cancer (HT-29), leukaemia (K562) and human 
breast carcinoma (MCF-7) tumour cell lines. Both C88 and C89 exhibited high antiproliferative 
activity, with IC50 values in the range 2-9 µM, values better than those of cisplatin in three cell lines 
(HeLa, HT-29 and K562). Karami et al. suggested that this high cytotoxicity could reflect the good 
solubility and lipophilicity of the complexes; in fact, the lipophilicity of the bridged complexes was 
related to the presence of two bulky PPh2 groups from 1,2-bis(diphenylphosphino)ethane which 
facilitate the transport through the cell membranes. Moreover, both complexes interacted with DNA 
through intercalation, and the 1,2-bis(diphenylphosphino)ethane bridge confers more flexibility to 
the structure, giving the possibility to make more interactions with DNA. Hadizadeh et al. [148] 
provided a detailed study about the influence on cytotoxicity resulting from increasing the distance 
between the two Pd(II) ions in dinuclear complexes. In that study, Hadizadeh et al. synthesized 
three dinuclear Pd(II) complexes with dithiocarbamate ligands (C90-C92, Figure 20); they 
evaluated the effect of hydrocarbon chain length (propylene, butylene and octylene) in the structure 
of these complexes on the anticancer activity compared with that of cisplatin. All three complexes 
were highly cytotoxic to the AGS (human gastric carcinoma), HepG2 (hepatocellular carcinoma) 
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and KYSE-30 (oesophageal squamous cell carcinoma) cell lines, with IC50 values better than those 
of cisplatin in all the cell lines. The cytotoxicity values for the three complexes were rather similar, 
although C90, in which the propylene chain connected the two Pd(II) ions, had lower IC50 values in 
all the cell lines with respect to the other complexes. Cell cycle analysis revealed that C90-C92 
arrested the cell cycle at G2/M and S phases. 
 
5. Photoactivated complexes 
In the quest for even more selective anticancer therapies, several approaches to localize the 
cytotoxic effects of the drug to the tumour site have been investigated as already outlined. One of 
these approaches exploits the use of light and its interaction with matter, the beneficial effects of 
which have been known since antiquity. Transition metal complexes, and in particular those 
containing platinum and palladium, having a wide variety of electronic transition state available are 
suitable candidates for photoactivation, and the use of a suitable ligand can aid and amplify the 
effect. For example, charge transfer transitions such as metal-to-ligand charge transfer and ligand-
to-metal charge transfer are usually intense, giving rise to the possibility of complete transfer of an 
electron from the metal to the ligand or vice versa in the excited state as well as irreversible 
photodecomposition (redox) reactions. 
In cancer therapy, the main application used in the clinic is radiotherapy; it involves the use of high-
energy radiation (X-ray) sometimes generated (internal radiotherapy) by specific radioactive metal 
isotopes such as cobalt-60, iridium-192, cesium-137 and palladium-103. Recently, the use of 
transition metal complexes has been investigated because their cytotoxic activity can be activated it 
they are irradiated by suitable light. Such activity is higher than that exerted in the dark and so is 
attributable to the activation of the species. 
In all cases, the aim is to produce activated species that can be detrimental for cancer cells, acting 
with more efficiency or differently with respect to drugs currently in use. It was proved that ROS, 
free radicals and molecular oxygen in its reactive singlet state generated within cells and are the 
causes of DNA damage. However, photoactivated chemical reactions able to produce in situ the 
anticancer drug, starting from a non-toxic prodrug, are also being investigated.  
The main approaches reported in recent years are X-ray radiotherapy, photodynamic therapy (PDT) 
and photoactivated chemotherapy (PACT); see Figure 26. 
Non-invasive radiotherapy has been widely used clinically for decades, whereby high-energy X-
rays or γ-rays are used to kill directly cancer cells, with all radiation converging exclusively on 
tumours; this reduces the effect of toxicity towards close tissues. Unfortunately, this type of 
32 
 
radiotherapy fails for hypoxic tumours, often resulting in insensitivity to the radiation [149]; at the 
same time, high dosages of radiation can damage normal cells, resulting in the development of 
secondary tumour. Heavy metal complexes and particularly platinum complexes have shown the 
possibility to enhance X-ray-induced cell death through Auger electron effects of the platinum atom 
under high-energy irradiation [150]. By X-ray irradiation, there is an Auger cascade effect due to 
inner-shell electrons in platinum; the emitted low-energy electrons give rise to ROS and free 
radicals around the platinum complex, thus damaging DNA by strand breaks. 
PDT is another medical approved technique for the treatment of specific tumours and uses UV-vis 
energy. The technique has mainly been used to transform molecular oxygen from the fundamental 
triplet state 3O2 to the excited singlet state 
1O2; this causes oxidative stress and the death of cancer 
cells [151-153]. PDT requires molecular oxygen in situ, low-energy light and a photosensitizer. The 
photosensitizer accumulates in the tumour tissue and is able to transfer efficiently the photon energy 
adsorbed to excite triplet oxygen into the singlet state and has an antitumour effect, avoiding the 
killing of normal cells. The photosensitizer must have strong absorbance at long wavelengths and a 
high 1O2 quantum yield. Porphyrin and porphyrinoid ligands and related metal complexes are often 
used often in this field because of their selectivity for malignant cells. PDT has the advantages of 
spatial and temporal control as well as the possibility of repeated doses [154-156], but because it 
needs dioxygen in situ, it is inactive in hypoxic conditions. Several platinum complexes that can be 
photoactivated by light have been investigated [157-159]. 
PACT is a more recent application against tumours; it also uses visible light and preferentially 
longer-wavelength red light, which is able to penetrate deep into tissue. In PACT, a suitable inert 
compound is transformed into the active anticancer agent through light irradiation; the process does 
not need the presence of molecular oxygen in situ and so can be applied in hypoxic conditions. The 
active compound can exert its action directly, behaving as a classic antitumour agent, but it can also 
generate in situ, during or because of the photoactivation, cytotoxic species such as ROS, free 
radicals and/or singlet state 1O2. 
Following these guidelines, Xie et al. [160] have recently reported four Pt(II) complexes obtained 
with 1,10-phenanthroline derivatives (C93, Figure 21). They have been tested as potential radiation 
sensitizers to increase the sensitivity of cancer cells to radiotherapy. In the absence of X-ray 
irradiation, the platinum complexes exhibited less antitumour activity in vitro against human cell 
lines less than cisplatin, with the compound with X = COOH being the most active. By X-ray 
irradiation, the inhibition of growth of A375 human melanoma cells increased in the presence of 
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such complexes; in contrast, they showed much lower cytotoxicity towards human normal cells. 
Such inhibition occurs by the induction of G2/M cell cycle arrest. 
The complexes also dramatically inhibit the activity of thioredoxin reductase, an enzyme 
overexpressed in many cancer cells and identified as a cancer target for the design of new 
anticancer drugs [161]. In the presence of the complexes, intracellular ROS overproduction, 
attributed to the Auger electron effect of platinum under X-ray irradiation, was observed; this 
triggers DNA damage, thus increasing radiosensitivity and the inhibition of tumour reproduction. 
Naik et al. [162] recently reported an example of PDT using a porphyrin motif. Porphyrins are 
widely used in PDT, but their platinum complexes are not, Naik et al. synthesized three 
tetraplatinum(II) complexes using a porphyrin scaffold (C94-C96, Figure 21) and investigated their 
light-induced anticancer properties in vitro. In each complex, the four Pt(II) atoms are located 
outside the porphyrin ring; each of them is stabilized by a pyridine, belonging to the porphyrin, and 
by two trans chloride ligands and one DMSO ligand (C94) or one chloride and two trans or cis 
ammonia ligands (C95 and C96, respectively).  
All the complexes exhibited excellent quantum yields of 1O2 production (Φ), which is the 
requirement for a compound to be used in PDT. A higher value (Φ =0.54) was obtained for C96 
than for C94 (Φ =0.42) and C95 (Φ =0.50), whereas for the precursor porphyrin, Φ =0.41. 
The potential PDT activity was investigated in the dark and after irradiation with light of 420 nm; 
tetraplatinum(II) porphyrins C94-C96 and the porphyrin precursor exhibited negligible toxicity in 
the dark towards both non-cancerous MRC-5 and HeLa cancer cells, whereas a photocytotoxicity 
600-1200 higher than their toxicity in the dark towards HeLa cells was found only for the Pt(II) 
complexes. This ratio is defined as the phototoxic index (PI) and is the ratio between IC50 in the 
dark and the IC50 in light (PI = IC50(dark)/IC50(light)). The best PI values were obtained with the 
ammonia Pt(II) complexes C95 and C96, which had IC50 values of 54 nM (PI = 655) and 37 nM (PI 
= 1210), respectively, on irradiation with light. Irradiation at lower energy (575 nm) also gave rise 
to photoactivity. The compounds also exerted phototoxicity (420 nm) towards cisplatin-sensitive 
A2780 and cisplatin-resistant CP70 human ovarian cancer cell lines (PI > 5260 and IC50 = 19 nM 
for C96). 
The activity has been correlated to the lipophilicity of the complexes, which favours their diffusion 
through the cell membrane, thus enhancing their cellular uptake. Confocal laser microscopy 
experiments confirmed a relevant uptake for the platinum porphyrins in HeLa cells, with selective 
accumulation in the nucleus. The lipophilicity allows C96 to increase the nuclear platinum content 
more than 30-fold as compared with that observed with cisplatin. Viscometry and NMR 
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experiments performed with C96 demonstrated that it was able to bind to DNA by coordination to 
the N7 atom of guanosine as well as by intercalation, although the N7 kinetic coordination is much 
slower than intercalation. The pronounced light-mediated cytotoxicity was attributed to a 
photoinduced DNA cleavage; C96 did not cause any DNA cleavage on incubation in the dark, 
whereas it produced significant cleavage of the supercoiled configuration (intact DNA) and an 
increase in intensity of the nicked band (damaged DNA) on irradiation with light. 
PACT is an approach towards better control of drug-action specificity through spatial and temporal 
activation [163-165]. PACT with coordination compounds is usually based on a photochemical 
reaction occuring at the metal centre [166,167]; instead Gamez et al. [168] reported the first 
example of a potential PACT compound obtained by the photochemical modification of a ligand(s) 
coordinated to a metal ion. 
The new strategy exploited the photoswitchable property of 1,2-dithienylethene derivatives; these 
are photochromic molecules that can be converted into either their open or their closed forms on 
exposure to visible or UV light [169]. Gamez et al. [168] prepared two ligands each containing the 
photoswitchable 1,2-dithienylethene moiety able to form Pt(II) complexes (C97 and C98, Figure 
21); the difference between two ligands consists in the replacement of hydrogen (C97) with the 
more electronegative fluorine atoms (C98) in the cyclopentenyl ring. The open/closed forms of the 
Pt(II) complexes C97 and C98 displayed different DNA-interacting properties and cytotoxic 
behaviours. Complexes, as [(trans-PtCl2(DMSO))2L] complexes, were prepared by the reaction of 
2 equiv of cis-[PtCl2(DMSO)2] with 1 equiv of the ligand in methanol at room temperature. The 
switching properties of C97 and C98 as well as those of their ligand precursors were verified by 
UV-vis spectroscopy in dichloromethane because the compounds are not soluble in water. In the 
absence of UV irradiation, characteristic bands attributed to the open form of the ligand were 
detected; irradiation with UV light at λ = 365 nm converts the open form to the closed form, 
redshifting the π-π* transitions of the species. This was observed both in the free form of the ligand 
and in the platinum species. On irradiation with visible light, the initial spectra are recovered for 
C97 and C98, indicating the reversibility of the photocyclization process. However, the closed 
forms of both complexes was stable when it was kept in the dark for at least 24 h in 
dichloromethane solution, whereas it partially interconverts to the open form when kept in daylight. 
The affinity between DNA and the open and closed forms of C97 and C98 was investigated by 
competitive binding studies using EB as a reference. The main result is the significantly different 
behaviours of the open and closed forms of both complexes. The closed form showed an affinity 
towards CT-DNA 6.5 and 5.5 times higher than that of the open form for C97 and C98, 
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respectively; in addition, C97 displayed a slightly better DNA affinity than C98, attributed to the 
unfavourable electrostatic repulsion with the phosphate backbone of the double helix due to the 
fluorinated cyclopentenyl ring of C98.  
The greater affinity of the closed complexes for duplex DNA was attributed to the different 
structural aspects between the open and closed forms. The open form is distinctly more voluminous 
than the closed form (about 12% longer and 25% wider) and, above all, the closed form is clearly 
more planar and more conjugated on ring closure, owing to a sterically favoured interaction with 
DNA. 
The open/closed forms of the complexes have drastically distinct DNA-interacting behaviours, with 
the closed forms modifying the DNA shape more efficiently. The closed form of C98 performs 
better than the close form of C97, which is the reverse behaviour compared with the competitive 
binding studies. 
Even more interesting is the fact that each isomer (particularly for C98) exhibits a different 
cytotoxic behaviour towards various cancer cell lines. The open/closed forms of C97 as well as the 
open form of C98 exhibited very poor cytotoxicity properties, whereas the closed form of C98 was 
active against most of the cancer cell lines tested. The best result was obtained with the DMS 53 
small-cell lung cancer cell line, which is the most common and most virulent of neuroendocrine 
cancers (IC50 =34.40 mM, 48 h of incubation). However, compared with cisplatin, the closed from 
of C98, depending on the cell line, is about four to eight times less active. 
Confocal microscopy indicated that all the compounds are capable of entering the cells; however, 
only the cytotoxic closed form of C98 showed a diffuse cytoplasmic staining and it is the only 
species colocalized with the nucleus of A375 cells, thus suggesting that its high cytotoxicity may be 
due (in part at least) to its ability to reach the nucleus. 
Sadler and co-workers [165, 170-175] have worked for several years on PACT, mainly regarding 
Pt(IV) complexes. They have focused on trans-diazido Pt(IV) complexes containing several 
substituents in the octahedral species. The diazido Pt(IV) complexes appeared to be very promising 
prodrugs [176] because they are inert and non-toxic in a biological environment in the dark and they 
exhibit high stability in the dark, allowing their potential release to the target, where they produce a 
potent cytotoxic effect on irradiation with visible light with new mechanisms of action [158, 177-
179].  
Recently, they reported a new series of photoactivable trans,trans,trans-diazidodihydroxodiamino 
Pt(IV) complexes able to form novel DNA adducts (C99-C101, Figure 21) [180]. They had 
demonstrated previously that replacement of one or two NH3 ligands with pyridine in the 
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trans,trans,trans-[Pt(N3)2(OH)2(NH3)2] led higher photocytotoxicity and visible-light activation 
[165,170]. The replacement of NH3 with methylamine and/or thiazole at the Pt(IV) centre generated 
potent photocytotoxicity, in particular towards the cisplatin-resistant cell line A2780cisR [180]. The 
new compounds C99, C100 and C101 have been synthesized following an analogous method of 
Kauffman and Cowan [181,182]. The synthesis provides the oxidation by H2O2 of the respective 
trans-diazido Pt(II) complexes C102 and C103 [165,183]. 
The compounds were stable in the dark for several months in biological conditions; because they do 
not react with 5′-guanosine monophosphate (5′-GMP) or L-ascorbic acid, they were stable in the 
dark with regard to hydrolysis and also glutathione reduction. 
The complexes show three main absorption bands at 365, 420 and 450 nm, and their photoactivable 
cytotoxic activity was investigated by their irradiation at such wavelengths. Irradiation in aqueous 
solution resulted in the loss of the Pt(IV)–N3 bond(s). Density functional theory and time-dependent 
density functional theory calculations attributed the photoreactivity to the presence of dissociative 
ligand-to-metal charge transfer/d-d excited states, which can be populated by irradiation with UV 
and visible light. 
In the absence of light, C99 and C100 were not cytotoxic to several cell lines tested, whereas C101 
had IC50 = 187 μM for A2780 cells. All of the compounds exhibited different and marked cytotoxic 
activity when irradiated; in particular, they exhibited potent activity towards A2780cisR cisplatin-
resistant ovarian cancer cells on irradiation with UV or blue light and, when irradiated with blue 
light (420 nm), they were also highly cytotoxic to the A2780, OE19 and HaCaT cell lines. 
They are more than an order of magnitude more potent towards HaCaT keratinocytes, A2780 
ovarian cancer cells, and OE19 oesophageal carcinoma cells than cisplatin, also showing particular 
potency towards cisplatin-resistant human ovarian cancer cells (A2780cisR). 
Their cytotoxicity, compared with that of similar compounds, highlighted that the replacement of 
the pyridine with a thiazole in C101 increased the UV phototoxicity in some cell lines; the 
replacement of ammonia with methylamine in C100 seemed to decrease the cytotoxicity of the 
thiazole without affecting the phototoxicity. All the results suggested that thioazole-containing 
complexes were more effective towards resistant cell lines, showing resistance factors close to 1 
(i.e. lack of cross-resistance to cisplatin). 
On irradiation, C99 and C100 exhibited significantly faster binding to 5′-GMP and DNA than their 
trans Pt(II) precursors or cisplatin. The products from photoreaction of C99 or C100 with 5′-GMP 
were investigated; the results indicated that one azido ligand and two bound hydroxyl groups were 
released during irradiation. A probably azidyl radical released together with a hydroxide radical 
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formed gave rise the reduction of Pt(IV) to Pt(II) and the formation of Pt(II)-5′-GMP complexes; 
the formation of a bisGMP adduct, afforded by the loss of the second azide, was detected in small 
amounts. The formation of Pt(II)-GMP species is in agreement with the density functional theory 
calculations on the lowest-lying triplet states of C99 and C100. The highly distorted lowest-lying 
triplet geometry, showing an elongated Pt–N3 distance and a reduced positive charge on the 
platinum centre, should favour azide release and the reduction of Pt(IV) to Pt(II). 
C99 and C100 bind to DNA in a manner substantially different from that of cisplatin; this could 
account for their activity towards the A2780cisR cisplatin-resistant cell line. 
Photoinduced binding with DNA oligonucleotide and with individual nucleotides revealed that 
photoactivated C99 and C100 formed both monofunctional and bifunctional DNA lesions, with 
preference for G and C, similarly to transplatin, but with significantly larger unwinding angles and a 
higher percentage of interstrand cross-links, with evidence for DNA strand cross-linking further 
supported by a comet assay.  
The products of the photoinduced platination reactions of DNA caused by C99 and C100 showed 
similarities with the products of the dark reactions of the Pt(II) compounds trans-[PtCl2(MA)(Py)] 
and trans-[PtCl2(MA)(Tz)], where MA is methylamine, Py is pyridine and Tz is thiazole. Following 
photoactivation, C100 reacted most rapidly with CT-DNA, followed by C99, whereas the dark 
reactions of both trans Pt(II) complexes with DNA were comparatively slow. C99 and C100 can 
therefore result in rapid potent photocytotoxicity and novel DNA lesions in cancer cells, with no 
activity in the absence of irradiation.  
The promising results obtained with these systems have led to further investigation of C99 to reveal 
in more detail the mechanism of the photoactivation/complex decomposition [180]. 
Irradiation of the Pt(IV) complex C99 with 5′-GMP in aqueous solution at pH 7.4 resulted in 
different Pt(II) products depending on the irradiating wavelength. Irradiation at 450 nm gave the 
monoGMP Pt(II) complex [Pt(N3)(MA)(Py)(5′-GMP)]
+ (C99a+) as the major species and the 
bisGMP Pt(II) complex trans-[Pt(MA)(Py)(5′-GMP)2]
2+ (C99b2+). In addition to C99a+ and 
C99b2+, two new compounds, C99c and C99e, were observed in high-performance liquid 
chromatography experiments on irradiation at 420 nm, whereas a further species (C99d) appeared 
on irradiation at 365 nm. These results are similar to those in the absence of dissolved molecular 
oxygen (i.e. under an argon atmosphere), thus excluding the possibility that dissolved molecular 
oxygen is involved in the Pt(IV) to Pt(II) reduction process. C99c, C99d and C99e contain NH3 
bound to Pt(II), suggesting that it is derived from the azide ligand. 
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By use of marked [15N=14N=14N]− azide ion, gaseous N2 directly released from Pt-N3 was detected. 
The photoreaction releases the N3
∙ radical but also probably the OH∙ radical (it was not detected 
because of its short lifetime). O2 is also formed; it is generated not by water molecules through 
energy transfer from a photosensitizer but directly from C99, and thus from coordinated hydroxide 
ligands. The presence of the singlet 1O2 form was detected; the quantity of generated 
1O2 is higher 
the shorter the wavelength. 
The production of ROS by the photodecomposition of the Pt(IV) complex C99 leads to an 
unexpected oxidation of guanine during the photoreaction with 5′-GMP. The reaction pathways of 
the C99-5′-GMP photoreactions were investigated, and the findings suggested that the 
photodecomposition of C99 involves the formation of platinum-nitrene intermediates and the 
formation of singlet oxygen, free azide, azidyl radicals and nitrogen gas. The oxidation of guanine 
is likely to arise from reactions of singlet oxygen and nitrene intermediates. The generation of 
singlet oxygen in the absence of oxygen gas and the oxidative damage to guanine may contribute to 
the potent photocytotoxic effects of this complex.  
 
6. Other complexes 
Many active complexes are difficult to rationalize in terms of molecular structure, both from the 
ligand and from the complex point of view. Currently, many of them, although active, are difficult 
to classify. Some of them have been tested in biological studies. In the last 3 years, several 
compounds have fallen in this category [184-191]; here we report those for which important results 
have been obtained in terms of antineoplastic as well as unconventional activity and a converging 
motif. 
Polynuclear platinum and palladium complexes have been widely investigated [9] and are still 
being investigated in synthetic and related studies applied to different chemical structures (Figures 
22-24). Polynuclear platinum complexes, structurally different from cisplatin, exhibit a different 
mode of DNA binding, circumventing cellular resistance. Mainly, the structural conformational 
changes induced by long-range interstrand and intrastrand cross-links are distinctly different from 
those induced by the mononuclear cisplatin and oxaliplatin [192]. Among them, the use of aliphatic 
polyamines is frequent because many of them, such as spermidine and spermine, are present in all 
prokaryotic and eukaryotic cells [193,194]. The prototype of this class (C104, Figure 22) has 
reached human phase II clinical trials [195]. In this period, other studies considered these motifs 
and obtained interesting results, such as the study of Menon et al. [196] on C104 and C105 (Figure 
22), where the cyclohexyl fragment has been inserted as a carrier ligand. Both compounds exhibited 
39 
 
significant antiproliferative activity, and C105 induces DNA interstrand cross-links, eliciting a 
unique dual mode of cell cycle arrest.  
Silva et al. [197] investigated trinuclear Pt(II) and Pd(II) complexes obtained with 
dipropylentriamine (norspermidine) (C106, Figure 22) in a metal-to-ligand molar ratio of 3:1. The 
Pd(II) complex showed a stronger antiproliferative effect than the Pt(II) complex towards three 
breast cancer cell lines, whereas normal cells were less sensitive to both compounds. The Pd(II) 
species reduced the number of colonies formed in a soft agar assay performed with the breast cancer 
cell lines more so than the Pt(II) species. A genotoxicity screen indicated that they are not genotoxic 
at 25 mM concentration. Trinuclear Pt(II) complexes with linear polyamines were considered by 
Hamad et al. [198] for activity against human ovarian tumour models with cis geometry for terminal 
platinum centres; one of them (C107, Figure 22) was more active than cisplatin, and its activity has 
been ascribed to the formation of long-range interstrand and intrastrand adducts with DNA. 
In research on polynuclear platinum and palladium complexes using linear polyamines 
Chtchigrovsky et al. [199] synthesized a series of trans-Pt(II) dinuclear complexes in which Pt(II) is 
also stabilized by one C–Pt(II) bond (C108, Figure 22); these compounds displayed cytotoxic 
activities in the micromolar range against many cancerous cell lines and did not cross-react with 
cisplatin in the A2780/DDP cell line. The slow formation of monoadducts to double-stranded 
DNAs as the major products was observed. These C–Pt and C–Pd compounds are organometallic 
systems recently investigated for their activity [200-204]. 
Several Berenil dinuclear Pt(II) complexes (Figure 23, C109) have been studied [205,206]. Two of 
them (where X is 3-ethylpyridine or 3-butylpyridine) exerted a strong antitumour effect on human 
breast cancer cells [205]. The results revealed apoptosis induction by those dinuclear Pt(II) 
complexes with the apoptotic potential being evidenced as primary lesions of DNA. Apoptosis 
induction, possibly enhanced by a contribution of targets other than DNA, seems to be an important 
factor in the mechanism of action of these compounds. The cytotoxic effects of both C109 
complexes cause mitochondrial dysfunction and activation of the caspase cascade. They might 
induce apoptosis by extrinsic and intrinsic pathways. The results in [206] demonstrated the 
remaining five Berenil dinuclear Pt(II) complexes enhanced oxidative stress formation in 
fibroblasts; this was ascribed to the increase of ROS generation, and to the decrease of antioxidant 
properties. Among all the complexes, those with two isopropylamine ligands are the most active; 
however, those with piperazine or 2-picoline ligands also increased the apoptotic profile compared 
with cisplatin, mainly relating to breast cancer cell metabolism. 
40 
 
Dinuclear Pt(II) tetraazolato-bridged complexes have been obtained and investigated in addition to 
previously synthesized similar species [207-209] (Figure 23, C110); the crystallographic 
characterization of one of them, cytotoxicity profiles, and in vivo antitumour efficacies were 
reported [210]. The cytotoxicity fingerprints of the complexes based on the JFCR39 cytotoxicity 
data were similar to one another but completely different from the fingerprints of clinical platinum-
based anticancer drugs, thus suggesting that the new tetraazolate compounds inhibited cell growth 
by means of a different mechanism including cellular uptake, and they largely circumvent cisplatin 
resistance. The complex with X is CH2COOC2H5, exhibited marked antitumour efficacy when 
tested in vivo on xenografts of PANC-1 pancreatic cancer in nude mice, highlighting the antitumour 
efficacy of these tetraazolate-bridged Pt(II) dinuclear complexes. 
The synthesis and characterization of Pt(II) dinuclear complex C111 (Figure 23) was reported in 
[211]; its cytotoxicity together with that of the Pd(II) analogue towards human breast cancer (MCF-
7) and human colon cancer (HT-29) cell lines was evaluated. Although the free form of the ligand 
did not show appreciable activity, both complexes showed growth-inhibitory activities, even better 
than for cisplatin, with the Pt(II) complex having the highest cytotoxic activity (IC50 = 41 μM). 
The trinuclear Pt(II) complex C112 (Figure 23) was synthesized [212]; in it the three Pt(II) centres 
are monofunctionalized with a chloride ligand. C112 affects the conformation of DNA more 
efficiently and reacts with glutathione much more slowly than cisplatin. The DNA adducts formed 
are of 1,4-GG type as well as of lesser extent, and the 1,3-GG intrastrand cross-links are very 
different from those 1,2-GG intrastrand cross-links formed by cisplatin. Its cytotoxicity is higher 
than that of cisplatin towards the MCF-7 and A549 tumour cell lines. The cellular inhibition mode 
of the monofunctional trinuclear platinum complex was examined by flow cytometry in MCF-7 
cells; C112 arrests the cell cycle mainly in G2 or M phase, whereas cisplatin arrests the cell cycle in 
S phase. C112 seems more accessible to DNA owing to the cationic nature and its stability in the 
presence of glutathione. C112 may be useful in nucleic acid research as an effective GG cross-
linking agent. 
A series of diazine-bridged dinuclear Pt(II) complexes have been prepared and studied in bioassays 
as potential anticancer agents [213]. The interaction with double-stranded DNA was determined 
through in vitro cytotoxicity assay in human fibroblasts (MRC5) and two carcinoma cell lines 
(A375 and HCT 116). All the complexes inhibited cell proliferation with inhibitory concentrations 
IC50 in the 0.5−120 μM range. The role of the bridging ligand and that of the tailored groups in the 
interaction with DNA were discussed. C113 (Figure 23) exhibited higher cytotoxicity potential in 
comparison with cisplatin, whereas C114 (Figure 23) exhibited activity comparable to that of 
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cisplatin and was less toxic in an assay with zebrafish embryos, causing no adverse developmental 
effects.  
Polynuclear complexes have been tested as telomerase inhibitors; molecules able to stabilize certain 
G-quadruplex structures, such as human telomeric G-quadruplex DNA (leading to inhibition of the 
telomerase activity) [214] and to promote G-quadruplex DNA (leading to oncogene 
downregulation) [215] exerted inhibition of tumour cell proliferation. G-quadruplexes, which 
consist of four-stranded nucleic acids, are described as having a high-order secondary DNA 
structure and they have received attention regarding their potential use in anticancer therapies [216]. 
These guanine-rich sequences exist in the promoter regions of several oncogenes and the telomeres 
at the end of the chromosomes. Telomerase is active and upregulated in approximately 85% of 
tumour cells, thus the telomeric G-quadruplex has been considered a potentially effective 
antitumour target. 
Zheng et al. [217] reported a tetranuclear Pt(II) complex obtained with two porphyrins (C115 and 
C116, Figure 24) showing high affinity and excellent selectivity for the G-quadruplex structure 
rather than double-stranded DNA. Studies indicated their good anticancer activities through dual 
effects, inhibition of the telomerase activity and repression of oncogene expression. The work 
suggested that the modulation of the shape and configuration of multinuclear metal complexes 
working on the bridging ligands (the porphyrin in this case) is a strategy for constructing geometry-
oriented G-quadruplex stabilizers and therefore anticancer drugs. 
Similarly, they investigated two dinuclear Pt(II) complexes (C117, C118, Figure 24) and found that 
both complexes (mainly C118) were able to selectively stabilize the human telomeric G-quadruplex 
and to significantly inhibit the activity of telomerase, probably due to interactions with the sugar-
phosphate backbone of the G-quadruplex. The IC50 is 0.113 μM for C118, indicating that it is one 
of the strongest known telomerase inhibitors. V-shaped dinuclear Pt(II) complexes can act as 
selective G-quadruplex binders and telomerase inhibitors although mononuclear Pt(II) complexes 
also exerted similar behaviour but with higher IC50 values (10 μM) [218]. 
Other dinuclear complexes have been studied [219] or previously discussed [62]. 
In recent years, sulfur-containing ligands such as dithiocarbamates and thiosemicarbazones and 
their transition metal complexes have received attention in the area of medicinal chemistry owing to 
their pharmacological properties, such as antiviral [220-222], antibacterial [223-226], antifungal 
[227-229], antiparasitic [230,231], and antitumor [131,232-238] activities. Among them, 
thiosemicarbazones are an important and versatile type of ligand because of the potential donor 
atoms that they possess; among which sulfur is of paramount importance in the metal-ligand 
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linkage. Pd(II) and Pt(II) complexes of thiosemicarbazone-derivatized molecules have been studied 
in depth by Matesanz and Souza [239]. Particularly, compounds in which the thiosemicarbazone 
side chain is attached at α position to a nitrogen-containing heterocyclic ring—namely, α-N-
heterocyclic thiosemicarbazones—are strong metal chelating agents and, moreover, some of the 
ligands in their free form also showed antineoplastic activity. The biochemical mechanism of action 
involves, among other mechanisms, ribonucleotide reductase inhibition and non-covalent DNA 
binding [240-245]. In recent years many complexes of Pt(II) and Pd(II) with thiosemicarbazone 
ligands have been reported that exhibit considerable cytotoxic activity, particularly in cisplatin-
resistant tumour cell lines. Pd(II) complexes are more active than Pt(II) complexes, probably due to 
greater affinity for sulfur ligands. Matesanz et al.[246] described four novel 2,6-diacetylpyridine 
bis(4N-tolylthiosemicarbazonato) Pd(II) and Pt(II) complexes (C119a-C119d, Figure 25). The 
ligands act as dianionic tetradentate donors coordinating to the metal centre in a square planar 
geometry through the N-pyridinic group, the N-iminic group and the sulfur atoms from one 
thiosemicarbazone arm; the fourth coordination position is occupied by the N-hydrazinic group of 
the other arm. The new compounds have been evaluated for antiproliferative activity in vitro against 
the NCI-H460, HepG2, MCF-7, A2780 and A2780cisR human cancer cell lines. The cytotoxicity 
data suggested that C119a, C119b and C119c may have important antitumour properties since they 
are capable of not only circumventing cisplatin resistance in A2780cisR cells but also of exhibiting 
high antiproliferative activity in MCF-7 breast cancer cells. A subsequent toxicity study in LLC-
PK1 renal cells showed that none of these compounds are toxic in vitro in the concentration range 
tested. The same research group reported a similar system in which the two aromatic groups are p-
chlorophenyl (C119e and C119f) [247]. Both the free form of the ligand and its Pd(II) and Pt(II) 
complexes have been evaluated for antiproliferative activity in vitro against the NCI-H460, T-47D, 
A2780 and A2780cisR human cancer cell lines and were active and capable of circumventing 
cisplatin resistance in A2780cisR cells. Both Pt(II) and Pd(II) complexes are particularly active on 
T-47D breast cancer cells. Parrilha et al. [248] synthesized metal complexes with 2-acetylpyridine-
N4-orthochlorophenylthiosemicarbazone (C120, Figure 25); they were assayed for their cytotoxicity 
towards MCF-7 breast adenocarcinoma and HT-29 colon carcinoma cells. The thiosemicarbazone 
and its complexes are cytotoxic. The Pd(II) complex C120b was twice as toxic as the Pt(II) 
complex, with an IC50 value ranging from 1.38 to 2.00 μM, but they are also toxic to non-cancer 
cells. 
Other examples of thiosemicarbazones studied by this research group are Pd(II) bischelate 
complexes of the type PdL2 in which the ligands are 4-phenyl-1-(acetone)thiosemicarbazone 
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(C121a), 4-phenyl-1-(2-chlorobenzaldehyde)thiosemicarbazone (C121b), 4-phenyl-1-(3-
hydroxybenzaldehyde)thiosemicarbazone (C121c), 4-phenyl-1-(2-
naphthaldehyde)thiosemicarbazone (C121d) and 4-phenyl-1-(1-nitro-2-
naphthaldehyde)thiosemicarbazone (C121e) (Figure 25) [131]. These complexes have a square 
planar geometry with two deprotonated ligands coordinated to Pd(II) through the azomethine 
nitrogen and thione sulfur atoms in a cis arrangement. The complexes exhibited higher 
antiproliferative activity than their ligands in the free form, with IC50 values between 0.01 and 9.87 
μM for different types of human tumour cell lines. In particular, C121c exhibited high antitumour 
activity against DU145 prostate carcinoma and K562 chronic myelogenous leukaemia cells, with 
low IC50 values (0.01 and 0.02 μM, respectively). 
Ramachandran et al. [130] synthesized and studied four new Pd(II) complexes of 2-oxo-1,2-
dihydroquinoline-3-carbaldehyde thiosemicarbazones with triphenylphosphine as a co-ligand, 
discussed in Section 4 (Figure 19). 
Shih et al. [249] proposed a Pd(II) complex with 3-arylsydnone-4-carbaldehyde-4′-
phenylthiosemicarbazones (C122, Figure 25). The ligands bind the Pd(II) centre by an O,N,S 
tridentate coordination mode through sydnone carbonyl oxygen, azomethine nitrogen and thiolate 
sulfur atoms, with the fourth position occupied by a chloride anion. The carbonyl oxygen of the 
sydnone ring is a good electron donor for metal coordination. Shih et al. designed these ligands 
considering that several sydnone compounds, a class of amphionic aromatic rings, exhibited some 
pharmacological activity, including antimicrobial, anti-inflammatory, analgesic and antipyretic 
activity. Cytotoxicity was tested on several human tumour cell lines, and the results revealed that 
the palladium complexes C122a-C122d have greater antiproliferative activity than 5-fluorouracil, 
with IC50 values in the range 0.45-2.25 μM. In particular, the complexes exhibited better activity 
than the corresponding ligands. Accordingly, the study of sydnonyl complexes with anticancer 
activity may support the development of these complexes in cancer therapy. 
Mansour and Mohamed [51] used the ligand N-(2-thiazolyl)-1H-benzotriazole-1-carbothioamide, 
which can be considered a cyclic derivative of a thiosemicarbazone, to form the Pt(II) and Pd(II) 
complexes C123a and C123b (Figure 25); both complexes are cytotoxic to the MCF7 cell line, with 
the Pd(II) species more active than the Pt(II) species. The complexes tested have square planar 
geometry with the ligand chelating the metal ion in the deprotonated form and with the sulfur and 
one of the nitrogen atoms bearing a triazole. The other two coordination positions are occupied, in 
the case of Pd(II), by two ethanol molecules and, in the case of Pt(II), by an ethanol and a chloride 




7. Biological studies 
The choice of the correct experimental procedure through which the biological activity of the drug 
is monitored and to possibly dissect its molecular mechanism of action is a crucial point. The exact 
mechanism of antitumour action of platinum-containing drugs (cisplatin as the reference 
compound) is not completely understood; however, DNA is often believed to be the main target of 
these drugs or at least the first target to be tested for novel metal complexes. 
In the last decade some experimental approaches have become the gold standard for the 
characterization of the activity against DNA of platinum/palladium compounds. These approaches 
range from cell-free assays, through which it is possible to interpret the “secret” of the molecular 
action, to in vitro cellular assays, which are useful to monitor the biological activities. In addition, 
some of these compounds have been studied in vivo, by it which was possible to discover the real 
antitumour efficacy.  
However, the question that most of the studies had to address before the successive in vitro cellular 
stage of the research was if the platinum or palladium complexes investigated are able to interfere in 
some way with the DNA structure. In other words, it was investigated if the molecule of interest 
was able to modify the DNA on the basis of the molecular similarity with cisplatin.  
Cell-free assays are useful to directly investigate the interaction between DNA and complexes, 
simplifying studies. Nevertheless, cell-free assays are not devoid of limits in terms of interpretation 
of results and often require the use of multiple approaches. In this section we consider and discuss 
the cell-free biological tests used in recent years to “biologically” characterize platinum/palladium 
analogues as anticancer agents, mentioning the most used techniques, focusing on the major 
technical progress for each approach, and providing specific examples of the most representative 
studies. The methods are schematized in Figure 27: 
 
7.1. UV-vis absorption spectrum analysis of CT-DNA  
Electronic absorption spectroscopy in the UV-vis range is one of the most common techniques used 
to study the interaction of metal complexes with DNA. The procedure exploits the UV-vis 
absorption spectrum of DNA, which has a band (200-350 nm) in the UV region, with maximum 
absorption at 260 nm. Metal complexes may bind DNA in different ways depending on their 
structure, charge, and type of ligands. The kind of binding translates into different changes in the 
absorbance features. Addition of the complex to a DNA solution generally results in 
hyperchromism and a bathochromic shift of the band at around 260 nm, when compared with blank 
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DNA, which is generally accepted to be consistent with the interaction of binding of compounds to 
DNA. Several studies considered in this review monitored the changes of absorbance of a DNA 
solution (often CT-DNA) with increasing concentration of DNA for fixed amount of complex, and 
calculated the binding constant (Kb). Icsel et al. [80] compared the binding strengths of different 
metal complexes, observing that Pt(II) complexes show somewhat higher DNA-binding affinity 
(fish sperm DNA in this case) than the corresponding Pd(II) complexes. In the case of compounds 
with supposed phototoxicity, spectroscopic approaches were useful to evaluate the changes in the 
absorption properties and photolysis of the metal complexes under investigation [180]. Absorption 
spectrum studies can also be performed at different wavelengths when the metal complex possesses 
intrinsic absorption features (e.g. at 665 nm for certain macrocycles with non-covalent abilities of 
DNA interaction) [250]. In addition, to evaluate the possible involvement of L-methionine as an 
accelerator of DNA-platinum complex formation, UV-vis spectrum analysis has also been used to 
monitor the possible binding of DNA with this amino acid [47]. 
 
7.2. Circular dichroism spectra  
Cisplatin, considered the metal complex of reference, acts as an antitumour agent through the 
induction of DNA structural modifications that can be summarized by the formation of covalent 
adducts able to create intrastrand and interstrand DNA cross-links. Nevertheless, several studies 
postulated a mechanism of action involving also an intercalating ability of the metal complexes. 
The stabilization of specific secondary structures of DNA (e.g. G-quadruplex structures) by a non-
covalent interaction can be experimentally followed by the circular dichroism (CD) approach. 
Several studies used the CD technique to evaluate DNA conformational changes resulting from the 
interaction between DNA and a metal complex. Usually, the approaches analyse the UV CD 
spectrum of CT-DNA (but also specific DNA sequences such as telomeric G-quadruplexes), which 
has a positive band at around 270-280 nm, due to base stacking, and a negative band at around 240-
250 nm, due to the helicity of B-DNA (bands that are enhanced by non-covalent interactions). In 
particular, intercalation should stabilize the right-handed B conformation of CT-DNA, enhancing 
the intensities of the two bands. Thanks to this approach, researchers demonstrated the ability of 
some metal complexes to selectively bind and stabilize the G-quadruplex conformation of DNA, 
whereas other studies could not demonstrate the supposed intercalating abilities of the compounds 
of interest [187,217]. Notably, the CD spectrum can also change in a dose-dependent manner as 




7.3. Impairment of DNA electrophoretic migration  
The most used experimental approach is based on the theory that DNA molecules, whether 
covalently or not covalently modified, should change their abilities to migrate in the canonical 
agarose gel electrophoresis assay. This approach has proved extremely informative, simple to 
perform, and often suitable to monitor the alterations induced in the tertiary structure of DNA [37]. 
Usually circular plasmid DNA is used as the source of the polynucleotide (but also RNA [72]), 
which, after electrophoretic migration, should appear in three forms (bands): the band that migrates 
most rapidly represents the supercoiled closed circular form (SC form), the band that migrates most 
slowly represents the open circular nicked form (OC form) and the intermediate (less represented) 
band represents the linear form. Changes in the proportions of these bands, and/or in migration of 
the expected DNA forms, are interpreted as alterations of the DNA structure. However, the 
interpretation of the results is not always simple. Even though the speed of migration of a 
covalently closed circular DNA (under the same experimental conditions in terms of buffers, 
voltage, etc.) depends on the number of superhelicoidal turns, such migration should also be 
influenced by other factors, such as intercalation in the double helix or DNA fragmentation, both 
phenomena dependent on the drug activity. So there is not always a simple change in the proportion 
of the amount of each band but there is often a heterogeneous mix of different phenomena 
[129,251]. With use of this technique, several studies demonstrated the induction of structural 
alterations of DNA attributable to covalent cisplatin-like modifications for both palladium and 
platinum compounds. Several authors determined the effect of platinum or palladium complexes on 
DNA that can be summarized as follows: changes in both the amounts and the migration of the two 
major DNA species (SC and OC forms) probably due to covalent modification that induced 
different levels of supercoiling or the creation of a “nick” in one of the two DNA strands; decrease 
in the amounts of the SC and OC forms in favour of the linear form of the plasmid, due to the 
creation of a double strand break of DNA; global decrease in the amount of DNA and/or migration 
below the SC form due to massive degradation of DNA. An additional not expected phenomenon 
has been documented by Jamshidi et al. [112], in which the binding of the platinum complexes to 
the DNA caused the appearance of a DNA smear in the agarose gel (due to random degradation) but 
at a molecular weight higher than that of the single expected bands. They explained the 
phenomenon by the involvement of coordination binding between the platinum complexes and 
DNA, retarding the rate of migration of the modified DNA. The impairment of electrophoretic 
migration has been improved by the use of experimental variants that increase the potential of the 
assay. To monitor the interference with DNA migration, Wu et al. [212] investigated the possible 
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DNA binding modes of a monofunctional trinuclear platinum complex, examining different cross-
links induced onto an 18-mer duplex derived from the breast or ovarian cancer susceptibility gene 
BRCA1. To gain further insight into changes in DNA conformation Hamad et al. [198], Utku et al. 
[251] and Prisecaru et al. [252] performed a drug-DNA incubation followed by targeted DNA 
digestion (enzymatic DNA restriction), analyzing in more detail the DNA structural alterations 
induced by the platinum complexes. To better understand the alteration of the tertiary structure of 
DNA, some researchers considered an additional experimental variant that is represented by the 
activity of DNA topoisomerase (type I). This enzyme, also called “nicking-closing enzyme” 
performs the conversion of supercoiled DNA to more relaxed DNA. This was used in some studies 
that monitored the inhibitory effect of platinum complexes of human topoisomerase I on 
supercoiled DNA or that simply caused a major unwinding of DNA, as deduced from the strong SC 
DNA band observed after treatment [48,52]. A few agarose gel electrophoresis assay studies were 
conducted to verify the abilities of palladium complexes to modify in some way the DNA structure; 
some authors found DNA modification attributable to DNA degradation or covalent adduct 
formation but, in general, at a concentration higher than the concentrations used for platinum 
complexes [80,126,147,253-256]. 
 
7.4. Thermal denaturation of DNA 
The structural modification of DNA induced by chemicals can alter the stability of the double helix 
and, in turn, the melting temperature, at which the two strands can be separated. Therefore, thermal 
denaturation profiles provide a convenient way to detect binding and the influence of adduct 
formation on the stability of the DNA double helix. Some authors calculated the melting 
temperature and the changes of the melting curves as a function of the presence of metal complexes 
with DNA. The classic approach is based on the calculation of the spectrophotometric absorbance at 
260 nm of a DNA solution (conventionally CT-DNA) at increasing temperature [80]. However, the 
thermal denaturation of DNA can also be done by fluorimetric approaches based on the use of an 
intercalating fluorescent dye such as SYBR® Green or EvaGreen®. The fluorescence resonance 
energy transfer approach, through which it is generally possible to detect spatial relationships 
between macromolecules (e.g. two DNA strands), has been used by several authors. Changes in 
fluorescence as a result of DNA denaturation are measured by use of a fluorescently labelled 
oligonucleotide mimicking the DNA sequence under investigation (e.g. human telomeric repeats, 
promoter-associated G-quadruplex DNA sequences such as c-kit and c-myc). The fluorescence 
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resonance energy transfer approach allowed a selective stabilization of human telomeric G-
quadruplex DNA structure by the metal complex investigated to be determined [217,218,257]. 
 
7.5. Inhibition of DNA/RNA polymerase activities 
Inhibition of the polymerase chain reaction (PCR), performed by DNA polymerase, is an enzyme-
based approach used to indirectly assay the modifications of DNA structure induced by metal 
complexes. Xu et al. [257] determined the complete PCR inhibition by two platinum complexes 
using a semiquantitative PCR approach. This kind of assay has attracted the interest of the scientific 
community because it can be applied to investigate the activity of metal complexes against specific 
human genomic loci (e.g. telomeric DNA repeats). In particular, human telomeric DNA is 
characterized by a short G-rich tandem repeat sequence d[(TTAGGG)n] that can form a structure 
named a G-quadruplex. Molecules that can bind and stabilize this structure inhibit the enzyme 
telomerase, which is more active in 85–90% of human cancer cells when compared with the normal 
cellular counterparts. Thus, the inhibition of telomerase activity could lead to a biological response 
in cancer cells and may be considered an appealing antineoplastic strategy for possible in vivo 
applications. To test the possible effect on the inhibition of telomerase activity, through G-
quadruplex modification, some authors tested metal complexes using the assay named telomeric 
repeats amplification protocol [217]. In addition, some authors exploited the DNA primer extension 
by the enzyme reverse transcriptase in the presence of an RNA template. Changes in RNA 
structure, induced by the metal complexes under investigation, led to inhibition of the enzymatic 
activity [72]. 
 
7.6. Fluorescence-based assay 
The fluorescent-based approaches have some advantages over other techniques that can be 
recapitulated as high sensitivity, wide linear concentration range and selectivity and are among the 
techniques most commonly used to study interactions between ligands and G-quadruplex structures. 
The fluorescent-based techniques can vary in terms of the kind of DNA intercalator used (e.g. EB, 
SYBR Green, etc.) and can be conducted in different ways: 
● Competitive EB displacement is an experimental approach to monitor the binding affinity of 
the complexes towards DNA (CT-DNA), and is based on the use of the most common 
intercalating compound EB, measured at 600-610 nm at different metal complex 
concentrations. The addition of a new metal complex, supposedly able to replace EB, should 
result in a decreased fluorescence intensity. The quenching ability of a certain complex has 
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been evaluated, as an example, by the calculation of the Stern-Volmer constant, also called 
the quenching constant [113,120]. Competitive fluorescence binding to EB-saturated CT-
DNA solutions was performed by Prisecaru et al. [252] using a high-throughput binding 
method, and they calculated the apparent DNA binding constant for the compound tested 
and the concentration required to displace 50% of the fluorophore. The same authors also 
calculated the relative kinetics of binding to DNA for each complex by measuring (at 
different intervals for 1 h) the fluorescence emission in the presence of saturated EB bound 
to CT-DNA. 
● Steady-state fluorescence spectra have been recorded, at increasing concentration of DNA, 
to monitor the DNA targeting ability of the fluorescent Pt(II) terpyridine–based conjugate 
1,8-naphthalimide [114]. By monitoring the fluorescent spectra, Zou et al. [258] 
demonstrated the differential emission of certain Pt(II) complexes when intercalated into 
double-stranded DNA or double-stranded RNA structures.  
● The fluorescence intercalator displacement assay, a method developed by Monchaud et al. 
[259,260], is a more recent approach by which several studies demonstrated the ability of a 
compound to stabilize a specific DNA structure (e.g. G-quadruplex of human telomeric 
sequences or specific promoter regions such as c-kit or c-myc) [261]. 
● To determine the mode of interaction, the DNA fluorescence quenching method has been 
used under the experimental condition of limited EB and Hoechst 33258 bound to CT-DNA. 
The different abilities of the two ligands (Hoechst 33258 is a minor groove binding ligand 
showing high preference for AT sequences, whereas EB is a classic intercalator and binds 
DNA with weak preference to GC-rich sequences of polynucleotide) allowed the binding 
features of the trinuclear Pt(II) series under investigation to be specifically monitored [252]. 
The biological cell-free assays described in the text and related references are reported in Table 1. 
 
8. Conclusions 
Although metal-based drugs in cancer chemotherapy have a history of about 40 years, there is still 
growing interest in the design of new metal-based anticancer agents to overcome the problems of 
clinically used drugs but with maintenance of their efficacy. Starting from the progenitor drug 
cisplatin, first approved by the FDA in 1978 for the treatment of ovarian carcinoma, the second 
generation of square planar Pt(II) complexes was introduced to improve safety (carboplatin), to 
imprive the spectrum of action (oxaliplatin), to overcome resistance (picoplatin) and to improve 
delivery (ProLindac, an oxaliplatin-like complex connected to a delivery polymer of 
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hydroxypropylmethacrylamide functionalized with a linker). All the Pt(II)-based drugs are 
administered intravenously or intraperitoneally because of sensitivity to low pH values. For oral 
activity, octahedral Pt(IV) complexes, such as satraplatin, have been developed. Today, about 10 
new platinum complexes are in clinical trials, and hundred of new complexes are preclinically 
tested each year. The race to synthesize new platinum and palladium complexes engages many 
scientists, and the design of novel metal complexes not only deriving from the cisplatin architecture 
but also different from it, such as monofunctional complexes, positively charged multinuclear 
complexes, trans complexes and octahedral complexes, is an important area of drug discovery. To 
improve the efficacy, an extraordinary variety of ligands and leaving groups have been proposed. 
Among them, the derivatization of metal complexes with bioactive molecules is a disputable 
strategy because there is not always a synergistic effect between the metal centre and the bioactive 
compound. Despite this, the design and synthesis of combi-molecules is an intriguing task of 
bioinorganic chemistry. 
A more recent application against tumour is the PACT strategy; it uses visible light, preferentially 
of longer wavelength (red light) able to penetrate deep into tissue, to activate a suitable inactive 
prodrug. In PACT a suitable inert compound, in this case a platinum or palladium complex, is 
transformed into an active anticancer agent through light irradiation. The active compound can exert 
its action directly, behaving as a classic antitumour agent, but it can also generate, during or 
because of the photoactivation, cytotoxic species such as ROS, free radicals and singlet-state 1O2. In 
recent years, some UV-vis photoactivable metal complexes have been proposed as anticancer 
agents and promising biological studies have been published. 
Finally, there is experimental evidence that some chemotherapeutic platinum complexes induce 
immunogenic cell death. One way in which chemotherapeutics can cause a tumour-specific immune 
response is by their triggering an immunogenic mode of tumour cell death, and thus these agents 
could act as "anticancer vaccines". It is probable that many highly promising immunogenic and/or 
immune-stimulating platinum and palladium candidates might have been neglected. The first 
attempt to explore the immune-modulating properties of platinum agents has been recently 
described by Wong et al. [262], opening the way to a new strategy for tumour therapy. 
 
Acknowledgements 
We acknowledge financial support from the Department of Base Sciences and Foundations and the 





2-Bu, 2-butyl; 2-Pn, 2-pentyl; Bu, butyl; CBDCA, 1,1-cyclobutanedicarboxylate; cBu cyclobutyl; 
cHex, cyclohexyl; cPn, cyclopentyl; DACH, 1R,2R-diaminocyclohexane; DMSO, 
dimethylsulfoxide; en, ethylendiamine; Et, ethyl; gluc, glycolate; Hept, heptyl; iBu, isobutyl; mal, 
malonate; Me, methyl; m-Tol, meta tolyl; o-Tol, ortho tolyl; p-Tol, para tolyl; NHcPn, 
cyclopentylamino; ox, oxalate; Pn, pentyl; py, pyridine; Ts, Tosyl; FID, Fluorescence intercalator 
displacement assay. 
Table 1. Biological cell-free assays described in the text and related references.  
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Figure 17. Pt(II) complexes for non-covalent interaction with DNA. 
Figure 18. Pt(II) complexes for non-covalent interaction with DNA. 
Figure 19. Pd(II) complexes for non-covalent interaction with DNA. 
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Figure 21. Photoactivated platinum complexes. 
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Figure 23. Polynuclear complexes.  
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Figure 26. Main approaches in the development of photoactivated complexes 






Table 1. Biological cell-free assays described in the text and related references. 
  
Cell-free biological assays References 
UV-vis absorption spectrum analysis 
of calf thymus DNA 
[47, 61, 64, 68, 71, 77, 78, 80, 83, 86, 112, 114, 116, 
119, 120, 123, 126, 128, 132, 133, 139, 160, 180, 
247, 250, 252, 253, 254] 
Circular dichroism spectrum 
[37, 40, 68, 112, 127, 187, 188, 212, 217, 218, 250, 
253, 257] 
Impairment of DNA electrophoretic 
migration 
[37, 39, 40, 47, 48, 52, 53, 56, 61, 63, 64, 65, 71, 79, 
80, 83, 88, 112, 122, 123, 126, 127, 129, 147, 180, 
188, 198, 199, 200, 212, 251, 252, 253, 254, 255, 
256] 
Thermal denaturation of DNA [80, 113, 217, 218, 257] 
Inhibition of DNA/RNA polymerase 
activities 
[72, 180, 217, 218, 257] 
Fluorescence-based assays 
[52, 77, 88, 113, 114, 116, 119, 120, 122, 123, 126, 

































































































































































































R=H, iPr, Bu, 2-Bu, iBu,
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C36a  n=1, L=dimethylamine
C36b  n=4, L=dimethylamine
C36c  n=1, L=isopropylamine
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2A=2NH3, en, 2EtNH2, DACH
2L=2Cl, CBDCA, mal, ox, glyc
X=CH2, (CH2)2, CH(CH3), C(CH3)2
R=OH, OMe, OEt, OPr, OBu, OPn,



































































































































A= 2NH3, 2E tNH2, NH3 and cHexNH2, en, DACH
























































C58 R =CH3 R '=CH3







































































































ClPPh3 C72 R =Me












































































































































































C97: X = H
















C94:  L1 = L3 = Cl, L2 =DMSO, n=0
C95:  L1  Cl, L2 = L3 = NH3, n=4




























































































n =1, 3, 4

























































































































































































































































Figure 27.  
 
 
 
 
 
